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Exercise tolerance, measured as peak oxygen consumption (V02 
peak), is very low in patients with end-stage renal failure 
undergoing maintenance haemodialysis. Due to their 
associated anaemia and low peak heart rates during maximal 
exercise it has been argued that the reduced blood oxygen 
carrying capacity and central cardiovascular limitations are 
primarily responsible for the poor exercise tolerance of 
these patients. However, others suggest that peripheral 
(skeletal muscle) limitations including impaired substrate 
utilization, muscle weakness caused by peripheral neuropathy 
and myopathy, malnutrition and general physical 
deconditioning are responsible for the poor exercise 
tolerance. The present thesis was therefore designed to 
study whether central cardiovascular function or anaemia or 
muscle weakness causes patients with end-stage renal failure 
to terminate exercise at workrates well below those achieved 
by healthy controls. 
The first study was designed to investigate the relationship 
between vo2 peak and variables relating to either isokinetic 
skeletal muscle function or blood oxygen carrying capacity 
in patients with end-stage renal failure undergoing 
maintenance haemodialysis. vo2 peak was measured during a 
maximum exercise test using a stationary cycle ergometer. 
Skeletal muscle function was measured using an isokinetic 
cycle ergometer and a Cybex II isokinetic dynamometer. 
There was a significant relationship between isokinetic 
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muscle strength and vo2 peak but not between haemoglobin 
concentration and vo2 peak· Therefore in renal 
haemodialysis patients, isokinetic muscle strength was a 
better predictor of exercise tolerance than variables 
determining blood oxygen carrying capacity. 
Recent human studies in which partial correction of the 
anaemia associated with end-stage renal failure was achieved 
with human recombinant erythropoietin (EPO), have shown that 
this therapy causes a significant increase in the vo2 peak 
of these patients. Several authors have interpreted these · 
findings as further evidence for a central cardiovascular 
limitation to maximal exercise in these patients. 
The second study was therefore designed to determine how EPO 
therapy alters physiological variables during submaximal and 
maximal exercise in patients with end-stage renal failure 
undergoing maintenance haemodialysis. Furthermore, the 
effect of EPO therapy on skeletal muscle function measured 
with an isokinetic dynamometer was studied. Haemoglobin 
concentrations and vo2 peak rose significantly with 
treatment. However, neither submaximal oxygen consumption 
nor blood lactate concentrations at exhaustion were 
influenced by EPO treatment. These findings plus the 
absence of a 'plateau' in oxygen consumption during maximal 
exercise indicate that peripheral oxygen supply was probably 
not the most important factor limiting maximal exercise in 
these patients either before or after EPO treatment. But 
peak isokinetic muscle strength improved significantly with 
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EPO therapy. Thus the improved exercise tolerance of 
patients with end-stage renal failure who receive EPO 
therapy, does not appear to be solely due to reversal of a 
postulated muscle hypoxia which develops during maximal 
exercise but could result from an effect of EPO therapy on 
other peripheral factors, including some that might relate 
to skeletal muscle contractile function. 
The objective of the third study was to determine whether 
patients with end-stage renal failure undergoing maintenance 
haemodialysis show morphological features suggestive of 
myopathic changes in the skeletal muscles of their lower 
limbs. Eight patients receiving chronic haemodialysis for 
end-stage renal failure consented to have open skeletal 
muscle biopsies performed. All of these patients had taken 
part in the first study and were therefore known to have 
poor exercise tolerance and skeletal muscle weakness. 
Tissues were examined by routine light and transmission 
microscopy. Fibre typing and sizing was quantitatively 
performed using computer-assisted morphometry. These values 
were within the normal population range and were not 
different from the controls. However, significant changes 
were found under light microscopy. These included fibre 
splitting, internalized nuclei, nuclear knots, moth eaten 
fibres, fibre degeneration and regeneration, increased 
content of lipid droplets and fibre-type grouping. Electron 
microscopy showed a large variety of non-specific 
abnormalities including mitochondrial changes, z-band 
degeneration, myofilament loss and accumulation of intra-
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cellular glycogen. This study, although unable to offer an 
explanation for the pathogenesis of the myopathy, clearly 
demonstrated morphological changes in the muscle which may 
be sufficiently severe to account for the muscle weakness 
and severely impaired exercise tolerance found in all of 
these patients. 
Hypertension and anaemia, both of which occur commonly in 
patients with end-stage renal failure undergoing maintenance 
haemodialysis, are often not controlled by adequate 
haemodialysis or blood transfusions, respectively. Atenolol 
is often the treatment of choice for the hypertension in 
patients receiving chronic haemodialysis. EPO partially 
corrects the anaemia associated with end-stage renal 
failure. Both forms of treatment are capable of influencing 
exercise tolerance during maximal exercise. 
Therefore, the final study investigated the possible effects 
of non-selective grouping of patients, who are either on EPO 
therapy or ingesting beta-blockers on the interpretation of 
studies of exercise tolerance in patients with end-stage 
renal failure receiving maintenance haemodialysis. The 
study found that patients undergoing chronic haemodialysis 
and receiving Atenolol, 100mg daily, had vo2 peak values and 
peak heart rates that were lower than values measured in 
control patients, without changes in peak isokinetic 
quadriceps muscle strength. Patients receiving EPO therapy 
and whose haemoglobin concentrations were similar to 
patients not requiring correction of their initially higher 
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haemoglobin concentrations, achieved comparable V02 peak 
values to those control patients. 
This study therefore questions the conclusions drawn by 
other studies, which have included patients on beta-blockers 
in their total sample without appreciating that the low peak 
heart rates measured in those patients and which were 
assumed to have limited the exercise tolerance of these 
patients, may have resulted from their use of B-blockers. 
The results of these four studies lead us to conclude that 
impaired skeletal muscle contractile function or impaired 
skeletal muscle recruitment or both, may be important, but 
currently underappreciated, factors responsible, in part or 
whole, for the low exercise tolerance found in patients with 
end-stage renal failure undergoing maintenance 
haemodialysis. 
A central cardiovascular limitation cannot fully explain the 
low exercise tolerance of these patients because the low 
peak lactate concentrations and absence of a 'plateau' in 
oxygen consumption during maximal exercise are not 
compatible with this interpretation. However, neither can 
skeletal muscle weakness fully explain the low peak heart 
rates and low peak rates of ventilation achieved by these 
patients as exercising heart rates and rates of ventilation 
are usually increased abnormally in persons with myopathy. 
It may, therefore, be possible that impaired recruitment of 
skeletal muscle fibres, resulting from either a central 
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motor dysfunction or peripheral neuropathy, may be another 
factor effecting the exercise tolerance of patients with 
end-stage renal failure undergoing maintenance haemodialysis 
during prolonged maximal exercise. 
These findings indicate that in order to optimise the 
rehabilitation potential of patients with end-stage renal 
failure undergoing maintenance haemodialysis, therapeutic 
interventions that aim to correct potential peripheral 
contributors to exercise intolerance, such as skeletal 
muscle weakness and impaired recruitment of skeletal muscle 
fibres, must be included. Thus the low haemoglobin 
concentrations of these patients should not be considered 
the exclusive guideline for therapy nor should anaemia be 
considered the only factor requiring correction in these 
patients. 
Further studies, possibly at the muscle cellular level, are 
necessary to understand the sequence of events responsible 
for the low exercise tolerance of patients with end-stage 
renal failure undergoing maintenance haemodialysis. 
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INTRODUCTION TO THE PROBLEM 
Exercise tolerance, as measured by the peak oxygen 
consumption (V02 peak l achieved during dynamic exercise 
using large muscle groups, is very low in patients with end-
stage renal failure undergoing chronic haemodialysis [Barnea 
et al., 1980; Kettner et al.,1984; Painter et al., 1986(a); 
Zabetakis et al., 1982] and in those who have undergone 
successful renal transplantation [Painter et al., 1986(a); 
Kempeneers et al., 1990]. In one study only 60% of 
haemodialysis patients were capable of a physical working 
capacity beyond that required simply to care for themselves 
[Gutman et al., 1981]. 
The mechanisms responsible for the very low exercise 
tolerance of these patients has yet to be definitively 
identified. The extensive literature on this subject 
indicates that opinion is divided between those who believe 
that the main cause of the reduced exercise tolerance in 
these patients is the associated anaemia [Barnea et al., 
1980; Kettner, 1982; Zabetakis et al., 1982; Zanconato et 
al., 1990; Lundin et al., 1991) causing impaired oxygen 
delivery to the active muscles [Moore et al., 1993). In 
contrast, others believe that impaired muscle contractile 
function associated with the renal failure is the primary 
factor [Kettner-Melsheimer et al., 1987; Robertson et al., 
1990] . 
Hence opinion is divided between those who believe (i) that 
either a central limi tation of oxygen delivery to muscle 
resulting from the anaemia, or a n assoc i ated impairment in 
oxygen uptake by the active musc l es [Moo re et al., 1993] 
explains the poor exercise tolerance of these patients, and 
those who favour (ii) impaired skeletal muscle contractile 
function, separate from both the anaemia and the postulated 
impairment in oxygen uptake by the active muscles. 
STATEMENT OF THE PROBLEM 
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Measurement of peak oxygen consumption (V02 peak) has been 
used almost exclusively to assess exercise tolerance in 
patients with end-stage renal failure. Earlier studies 
concluded that because these patients were anaemic and their 
V02 peak were low, the reduced haemoglobin concentration 
must be the major factor limiting their exercise tolerance 
[Barnea et al., 1980; Kettner, 1982]. Accordingly, it was 
concluded that as the anaemia could not be improved in the 
long term without administration of either blood products or 
erythropoietin, nothing of significance could be done to 
improve the poor exercise tolerance of these patients. 
However, subsequent studies using recombinant human 
erythropoietin (EPO) or blood transfusions, both of which 
increased haemoglobin concentrations, showed that these 
interventions improved the exercise tolerance of these 
patients [Graf et al., 1987; Mayer et al., 1988; Clark et 
al., 1988; Canadian EPO Study Group, 1990]. These findings 
could support the interpretation that the anaemia was the 
principle cause of the poor exercise tolerance of these 
patients. 
However, closer inspection of these studies showed that the 
increase in haemoglobin concentration did not necessarily 
correlate with the improvements in V02 peak [Lundin et al., 
1991; Metra et al., 1991]. 
Another finding which cast doubt on this theory of a central 
cardiovascular limitation for exercise tolerance in these 
patients was the low peak blood lactate concentrations 
achieved by these patients during maximal exercise [Sagiv et 
al., 1991]. In a recent review by Katz et al. (1990), it 
was concluded that exercise under conditions of impaired 
oxygen supply should result in increased blood lactate 
concentrations. Thus if their exercise tolerance is limited 
by impaired oxygen delivery to, or oxygen uptake by the 
active muscles, peak blood lactate concentrations in 
patients with end-stage renal failure undergoing chronic 
haemodialysis should be higher than values found in normal 
healthy subjects during maximal exercise. 
In contrast, these patients achieve V02 peak values that are 
approximately 50% of age predicted values [Barnea et al., 
1980) with peak blood lactate concentrations of only± 5 
mmo1.1-l [Roseler et al., 1980; Sagiv et al., 1991]. If, as 
suggested, oxygen supply limits peak exercise in these 
patients then their peak blood lactate concentrations should 
be much higher. Hence, the peak blood lactate levels found 
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in these patients, although significantly above restir.g 
values, are too low to explain why they terminate exerc i se 
at such low workloads [Sagiv et al., 1991 ) . This s ugg~sts 
that aerobic energy production during max i ma l exercise i n 
patients with end-stage renal fa ilure undergo i ng chror.:c 
haemodialysis, may not be the most i mpor t ant factor l imi ting 
their exercise tolerance. Similar findi ngs have also been 
found in patients after undergoing either renal or cardiac 
transplantation [Kempeneers et al., 1990; Kavanagh et al., 
1979] . 
Robertson et al. (1990), quantified the improvement in 
exercise tolerance produced by EPO therapy in anaemic 
patients with end-stage renal failure, who were undergoing 
chronic haemodialysis. These authors suggested that s i nce 
the patients' mean V02 peak improved by cnl y 17%, despite a 
64% improvement in haematocrit and arter i a l oxygen content, 
some as yet unidentified factor besides oxygen transport to 
tissues was the major factor limiting their peak exercise 
performance. Furthermore, Robertson et al. {1990) found 
quadriceps muscle strength, measured using a Cybex II 
Isokinetic Dynamometer {Lumex Corp, Ronkonkoma, NY), to be 
the single factor that best correlated wi th the V02 peak of 
these patients {r = 0.65). Thus they concluded that muscle 
weakness may be an important determinant of V02 peak i n 




The hypothesis tested in this thesis is that skeletal muscle 
contractile factors are an important contributor to the poor 
exercise tolerance of patients with end-stage renal failure 
undergoing chronic haemodialysis. 
SCOPE OF THIS STUDY 
The purpose of this thesis was, therefore, to investigate 
the relative roles that both anaemia and muscle weakness 
played in the low exercise tolerance of patients with end-
stage renal failure undergoing chronic haemodialysis. 
The first study was designed to determine whether skeletal 
muscle function, measured as isokinetic muscle strength, or 
blood oxygen carrying capacity, measured as total blood 
haemoglobin content, better predicted peak oxygen 
consumption in patients with end-stage renal failure 
receiving chronic haemodialysis. It was concluded from this 
study that muscle strength was highly associated with the 
poor exercise tolerance in these patients. 
In the second study, a group of anaemic patients with end-
stage renal failure undergoing chronic haemodialysis were 
treated with EPO. This study showed that both V02 peak and 
isokinetic muscle strength improved with EPO therapy. It 
was concluded that EPO therapy enhanced the exercise 
tolerance of these patients by mechanisms not solely related 
to an increased haemoglobin concentration and hence 
increased oxygen delivery to the active muscles. The 
finding that isokinetic muscle strength increased following 
EPO treatment is compatible with the inte rpretation t hat 
skeletal muscle function influences t he exercise tolerance 
of these patients, regardless of their haemoglobin 
concentrations. 
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The above findings led to a study of the effects of chronic 
renal failure on skeletal musc l e morphol ogy in patients with 
end-stage renal failure undergoing chroni c haemodialysis. 
Therefore, the third study described the morphological 
features of the myopathy assoc i ated wi th chronic renal 
failure. It was found that the muscles of patients 
undergoing chronic haemodialys i s for chronic rena l fa ilure 
show significant morphologica l abnorma l i ties. The severity 
of these changes suggest that they might explain the 
impaired skeletal muscle function of these patients. 
The fourth study evaluated the effects of the use of 
medications commonly prescribed in patients with 
hypertension, including the beta-receptor antagonists, on 
the exercise tolerance of patients with end-stage renal 
failure. These agents are known to impair the exercise 
tolerance of normal, healthy subjects. 
Thus the fourth study was designed to investigate the 
effects that various medications such as the beta-blocker 
receptor agonist, atenolol, and EPO have on the exercise 
tolerance of patients with end-stage renal failure 
undergoing chronic haemodialysis. 
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It was found that exercise tolerance, as well as peak heart 
rates, of the patients receiving atenolo l were significantly 
lower than values in patients not receiving this agent. 
Furthermore, no differences in exerc i se tolerance nor muscle 
strength were found between patients on maintenance EPO 
therapy and patients not on EPO but with similar haemoglobin 
levels. 
Results from this study suggest that patients with end-stage 
renal failure undergoing chronic haemodialysis and who are 
receiving beta-blockers should not be included in studies 
investigating factors explaining the poor exercise tolerance 
of this group of patients. Inclusion of these patients in 
exercise-related studies may well reduce the mean peak heart 
rates and exercise tolerance of the total group by 
mechanisms unrelated to the primary disease. Since several 
studies cite low peak heart rates as evidence for a central 
(cardiovascular) limitation to peak exercise in these 
patients, the exclusion of patients on beta-blocker therapy 
from these exercise studies may be important and could alter 
the conclusions drawn in some of those studies. 
In summary, since anaemia is characteristic of end-stage 
renal failure, it has always seemed reasonable to assume 
that reduced oxygen delivery to the active muscles during 
dynamic exercise must be the most important factor limiting 
the exercise tolerance of these patients. Furthermore, the 
finding that EPO which partially corrects the anaemia 
associated with end-stage renal failure, also improves the 
exercise tolerance of these patients, appeared to support 
the oxygen-deficiency theory. 
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However, the studies undertaken in this thesis suggest that 
impaired skeletal muscle function may have an important role 
to play in contributing to the premature termination of 
exercise tolerance of patients with end-stage renal failure 
undergoing chronic haemodialysis. The important findings in 
these studies which support this conclusion include: 
(i) the significant correlations between V02 peak and 
skeletal muscle strength measured isokinetically; 
(ii) improvement of both skeletal musc l e function and V02 
peak after EPO therapy; 
(iii ) EPO therapy did not increase oxygen consumption during 
submaximal exercise even at the maximal work-load achieved 
before EPO therapy. Hence an increased oxygen supply to the 
active muscles after EPO therapy cannot explain why patients 
were able to continue to a higher maximal work-load; 
(iv) severe morphological abnormalities are present in the 
skeletal muscle of these patients; and 
(v) heart rates, rates of ventilation and most importantly, 
blood lactate concentrations are low at peak exercise in 
these patients. 
It would be an extreme oversimplification to suggest that 
muscle weakness alone explained all of our findings. The 
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multisystemic pathologies, as outlined in Fig 2.1, must 
surely all contribute towards the low exercise tolerance of 
patients with end-stage renal failure undergoing maintenance 
haemodialysis. The autonomic dysfunction in haemodialysis 
patients is very likely to contribute to the low peak heart 
rates recorded in these patients. Whilst it is true that 
muscle weakness may prevent these patients from reaching 
higher peak blood lactate concentrations, it is equally 
possible that the reduced activities of key glycolytic 
enzymes and the metabolic acidosis restrict the lactate 
production in these patients. Furthermore, the skeletal 
muscle morphological abnormalities present in these patients 
may be the result of metabolic dysfunction. It is possible 
that EPO therapy partially corrects the metabolic 
dysfunction which may inturn improve skeletal muscle 
function. 
Each patient, who voluntarily consented to participate in 
the various studies, underwent a full medical examination by 
a senior renal physician prior to testing. All were on 
stable medical regimens, diets, and haemodialysis programmes 
involving a 12 hr.week-1 haemodialysis regimen. PCR (protein 
clearance ratio) and KT.v-1 (K = constant; T = duration of 
haemodialysis; and V = blood volume of patient) were not yet 
being used to assess adequacy of dialysis. However, the 
clinical condition was regularly monitored to assess 
adequacy of dialysis. 
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LIMITATIONS OF THIS STUDY 
The greatest limitation in this study was the availabi l ity 
of patients. Factors affecting the availability of su i table 
patients included "Third World" conditions such as lack of 
transport for the patients; poor communication caused by 
language differences; insufficient funds for treatment 
facilities or research; as well as unfamiliarity of exercise 
testing procedures. As EPO was only being introduced to 
South Africa at the time of this study, we were able to 
administer the drug to only 5 of the patients, one of whom 
did not wish to be part of the study. In order to get the 
sample size for these studies it was necessary to use 
patients from 4 major provincial hospitals. Since these 
hospitals are not in reasonable traveling distance from one 
another I had to relocate on two occasions. No objective 
scoring system was developed to test the relationship 
between skeletal muscle morphological abnormalities and 
skeletal muscle function. Such a scoring system would have 
improved the scientific merit of this thesis. 
12 
CHAPTER 2 
REVIEW OF THE LITERATURE 
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Most patients with end-stage renal failure are entered into 
a renal dialysis programme before they undergo renal 
transplantation. Lack of donors or tissue incompatibility 
often means that patients must wait several years before 
undergoing successful renal transplantation. A number of 
studies have indicated that these patients should be 
encouraged to commence a regular programme of moderate 
physical activity as soon as possible in order to optimize 
their rehabilitation potential [Goldberg, 1984; Shalom et 
al., 1984; Zabetakis et al., 1982; Carney et al., 1987; 
Goldberg et al., 1983; Hagberg et al., 1983]. 
These studies have reported several important benefits of 
regular exercise including increased exercise tolerance 
sufficient to allow the patient to cope with a wider range 
of daily activities [Shalom et al., 1984 ] , reductions in 
blood pressure so that patients require lower doses of anti-
hypertensive medications [Hagberg et al., 1983], reduced 
feelings of depression leading to increased performance of 
pleasant activities [Carney et al., 1987] and a rise in 
haemoglobin concentrations in the absence of plasma volume 
changes [Goldberg et al., 1980]. 
1-' 
The factors limiting the exercise tolerance of renal 
patients, who are either on dialysis or wto have undergone 
successful kidney transplantation, need to be clarified 
before safe and effective exerc i se can b~ prescribed. 
Prescription of exercise, as in any clini =~l set ting , should 
meet 3 fundamental criteria:-
(a) Assure regular participation in physica l activity; 
(bl Ensure that the chosen physical activity will not harm 
the patient (for example, contact sports are not 
acceptable since damage caused by a n external force may 
easily damage a dialysis ' access si te ' or transplanted 
kidney); 
(c) Maximise the potential to increase ft:.nctional capacity 
and health status. 
Programme flexibility is needed so that the limitations 
imposed by the disease can be accommodated. Each category 
of renal patient, therefore, requires a p~ograrnme specially 
tailored to their specific requirements a~d which 
encompasses realistic goals. 
FACTORS AFFECTING THE EXERCISE TOLERANCE OF HAEMODIALYSIS 
PATIENTS 
Patients with end-stage renal failure requiring chronic 
haemodialysis have poor exercise tolerance, usually measured 
as a reduced peak oxygen consumption (V02 peakl [Barnea et 
al., 1980; Kettner et al.,1984; Painter et al., 1986(a); 
Zabetakis et al., 1982]. However, the predominant 
mechanisms causing this impaired exercise tolerance, which 
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may also contribute to a reduced level of habitual physical 
activity, are a matter of debate. 
Determinants of physical performance include the capacity 
for skeletal muscle energy production (aerobic and anaerobic 
processes), neuromuscular function (muscle strength, co-
ordination and technique), joint mobility and psychological 
factors (for example, motivation and self-discipline) 
[Astrand et al., 1977]. 
(i) Capacity for Aerobic and Anaerobic Energy Production 
The conventional explanation for the low exercise tolerance 
of these patients has centered on the belief that oxygen 
supply to, or utilization by the active muscle mass, or 
both, is inadequate during exercise especi ally of near 
maximal intensity [Painter et al., 1987; Moore et al., 
1993]. Accordingly, measurement of the V02 peak has been 
used frequently to estimate exercise tolerance in 
haemodialysis patients [Barnea et al., 1980; Painter et al., 
1986(a); Zabetakis et al., 1982; Painter et al., 1987]. 
Aerobic Energy Production 
Aerobic energy production is dependent upon the supply and 
utilization of oxygen. Thus it is important to understand 
the relationships which exist between the variables which 
control oxygen uptake. 
The Fick principle [Little, 1985), which relates V02 (oxygen 
uptake_ ml 02.min-l) at any workrate to the cardiac output 
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(CO_ L.min-1) and the arteriovenous oxygen difference (D(a-
v)o2 _ ml 02.m1-l of blood), can be expressed as follows: 
COX D(a - v)02 ... eqn 1 
Equation 1 can be simplified by expressing cardiac output as 
a function of HR (heart rate_ beats.min-1) and SV (stroke 
volume_ ml.beat-1) and arteriovenous oxygen difference as a 
function of Hb (haemoglobin_ g.1-l) and Sa02 - Sv02 
(arterial oxygen saturation - mixed venous oxygen 
saturation). Thus 
V02 = HR x SV x 1.34Hb[Sa02 - Sv02] ... eqn 2 
Hence, according to the Fick principle, factors directly 
involved in, but not necessarily limiting,aerobic energy 
production include cardiac output (CO ) expressed as the 
product of heart rate (HR) and stroke volume (SV), 
haemoglobin concentration (Hb), and the difference between 
the percentage saturation of oxygen in arterial and venous 
blood, multiplied by a conversion constant of 1.34 ml02.gHb-
l 
It should also be remembered that cardiac output (CO) may be 
influenced by peripheral factors such as change in total 
peripheral resistance (TPR) according to the following 
equation:-
CO= BP.TPR-1 ... eqn 3 
(BP= Blood Pressure) 
These peripheral influences on cardiac output may be 
relevant because of the role of the kidneys in regulating 
blood pressure through effects on blood volume and release 
of vasoactive hormones such as renin, and which may 
therefore be altered in patients with end-stage renal 
failure. 
Pulmonary Ventilation 
The lungs provide the initial interface for gaseous 
exchange. Furthermore, minute ventilation (VE) influences 
V02 according to the following equation:-
... eqn 4 
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Fr02 and FE02 are the fractional concentrations of oxygen in 
inspired and expired air, respectively. It should be noted 
that VE only effects V02 in extreme conditions and VE and 
FE02 alter accordingly to keep V02 constant. 
Their is no evidence to suggest that impaired pulmonary 
ventilation may contribute to the low exercise tolerance of 
renal haemodialysis patients. However, pulmonary 
congestion, which should not be present in patients 
receiving adequate haemodialysis, may affect exercise 
tolerance [Painter et al., 1987) by reducing gaseous 
exchange in the lungs. 
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Arterial Oxygen Content 
In healthy subjects, the highest oxygen uptake that an 
individual can achieve during dynamic exerc ise using l arge 
muscle groups is influenced by the oxygen content of the 
arterial blood [Ekblom, 1986 ] . Patients with end-stage 
renal failure almost always develop severe anaemia [Guyton 
AC, 1981]. Decreased haemoglobin concentrations can 
therefore negatively influence the arterial oxygen content 
and can therefore influence the capacity for aerobic energy 
production [Moore et al., 1993]. 
Red cell 2,3-diphosphoglycerate concentration is increased 
in anaemia [Ganong, 1989]. At rest, the extremely low 
haematocrit (average 20% to 25%) and consequently low oxygen 
content is partially compensated for by a rightward shift of 
the oxygen-haemoglobin dissociation curve caused by 
metabolic acidosis and increased 2,3-diphosphoglycerate 
concentration [Ganong, 1989] characteristic of end-stage 
renal failure. This right shift causes more oxygen to be 
released to the tissues as a result of the decreased 
affinity of haemoglobin for oxygen at low oxygen tensions 
[Ganong, 1989]. Whether or not this mechanism is able to 
compensate fully for the anaemia and so to cope with the 
increased demand for oxygen use during exercise, remains to 
be investigated [Painter et al., 1987]. 
Significant correlations between haematocrit and exercise 
tolerance and haemoglobin concentrations and peak oxygen 
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consumption have been found in children [Ulmer et al., 1978] 
and adults [Zabetakis et al., 1982] with end-stage renal 
failure. However other workers did not find a correlation 
between exercise tolerance and haematocrit [Barnea et al., 
1980], or between V02 peak and haematocrit following renal 
transplantation [Painter et al., 1984], or when the 
haematocrit was increased following blood transfusions [Sill 
et al., 1972]. 
Recombinant human erythropoietin (EPO) which partially 
corrects the anaemia associated with end-stage renal 
failure, causes significant increases in exercise tolerance 
of haemodialysis patients, even in the absence of an 
exercise training programme [Mayer et al., 1988; Canadian 
Erythropoietin Group., 1990; Robertson et al., 1990]. These 
findings have led researchers to believe that the increased 
haemoglobin concentration improves peripheral oxygen 
availability thereby resulting in a significantly higher 
exercise tolerance of patients with end-stage renal failure 
[Graf, Mayer & Thum, 1987(abs); Mayer et al., 1988; Lundin 
et al., 1991). The conventional interpretation of this 
finding would be the oxygen-deficiency or "anaerobic" theory 
of fatigue, which holds that low haemoglobin concentrations 
and low arterial oxygen content are the main cause of 




It has been suggested that impaired myocardial function can 
decrease exercise tolerance in haemodialysis patients 
[Bornstein et al., 1975; Scheer et a l ., 1975; Uroaka et al., 
1975; Bullock et al., 1984]. Cardiac output, a function of 
heart rate and stroke volume (see eqns 1 and 2 ) or blood 
pressure and total peripheral resistance (see eqn 3), is 
linearly related to whole body oxygen consumption. 
Therefore, abnormalities in either heart rate, stroke 
volume, or the regulation of blood pressure or total 
peripheral resistance may adversely affect the capacity for 
aerobic energy production and hence the exercise tolerance. 
In patients with end-stage renal failure, resting cardiac 
output is typically increased [Ikrarn et al., 1983] due to 
anaemia and fluid overload [Mayer, 1989]. Impaired 
myocardial contractility shown by declining stroke volume 
and ejection fraction with rising end-systolic and end-
diastolic volumes, has been described in these patients even 
at rest [Harnpl et al., 1985]. Low left ventricular ejection 
fractions have also been correlated with low exercise 
tolerance in these patients [Bullock et al., 1984). All 
these findings suggest a central, cardiac limitation to 
exercise tolerance in these patients. 
Dysfunction of the autonomic nervous system resulting from 
the underlying uraemia [Mallarnaci et al., 1986), may be 
responsible for the low peak heart rates measured during 
maximum exercise in patients with end-stage renal failure 
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undergoing haemodialysis [Painter et al., 1984]. Studies 
have demonstrated that despite comparable resting heart 
rates, haemodialysis patients have lower heart rates at 
similar work intensities, as well as l ower peak heart rates, 
than do healthy sedentary controls [Kettner et a l ., 1984; 
Zabetakis et al., 1982; Painter et al., 1986 (a )] . However, 
a lower peak heart rate is to be expected since these 
patients also terminate exercise at significantly lower peak 
workloads. 
Impaired left ventricular function, possibly due to 
compromised contractile function or increased after-load due 
to hypertension, or both, will adversely affect stroke 
volume [Painter et al., 1987]. Negative inotropic states 
may result from hyperkalaemia, hypocalcaemia, 
hypermagnesaernia and acidosis [Ayus et al., 1981 ] ; all of 
which are features of the associated uraemia. Increased 
left ventricular afterload may be caused by hypertension, 
anaemia, and shunting through the arteriovenous fistula 
[Capelli et al., 1977]. However, the arteriovenous fistula 
created for renal haernodialysis appears not to produce 
significant effects on heart rate, stroke volume, arterial 
pressure, and right atrial pressure at peak levels of 
exercise [Payne et al., 1972). 
Thus physical activity in haemodialysis patients can be 
further compromised as a result of a reduced cardiac output, 
resulting both from a diminished heart rate response to 
exercise and a reduced stroke volume. 
22 
In addition, hypertension, associated with renal failure, 
has often been treated with beta-receptor antagonists 
(beta-blockers) in patients undergoing chronic haemodia l ysis 
[Friedman E, 1979). The detrimental effects of beta-
blockers on exercise performance in healthy subjects are 
well known; in particular there is a reduction of maximal 
heart rate and reduced time to fatigue during maximal 
exercise [Van Baak, 1988). However, despite these well 
known ergolytic effects of beta-blockers, many authors 
studying the exercise tolerance of renal patients persist in 
grouping patients, irrespective of whether or not they are 
receiving beta-blockers, and drawing conclusions about the 
factors which might limit these patients' exercise 
capacities including their low peak heart rates [Painter et 
al., 1986(a); Kettner-Melsheimer et al., 1987; Moore et al., 
1993 J • 
Clearly these conclusions will be influenced by the nature 
of the medications used by the patients. Hence there is a 
need to exclude those patients, who are on medications that 
might either enhance or impair V02 peak, from clinical 
trials designed to investigate factors limiting the exercise 
tolerance of these patients. 
Muscle Blood Flow 
Painter et al. (1987(a)) have proposed a hypothetical model 
which suggests that the metabolic acidosis and autonomic 
dysfunction associated with chronic renal failure may lead 
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to generalised arteriolar vasodilation which would result in 
a failure to redistribute blood flow awa y from non-working 
tissues during exercise. Thus t hey conc luded that a reduced 
blood supply to the active musc l e groups during exhaustive 
exercise may limit the maximal exercise capacity of patients 
with end-stage renal failure undergoing chronic 
haemodialysis. 
However, since muscle blood flow in these patients, has yet 
to be measured during maximal exercise, no definite 
conclusions regarding reduced muscle blood flow during 
dynamic exercise can be drawn at present. 
Substrate Utilization 
During exercise both carbohydrate and fat are essential 
substrates for the production of energy [McArdle et al., 
1981). Several metabolic abnormalities affecting the 
utilization of carbohydrate and fat have been identified in 
haemodialysis patients [DeFronzo et al., 1981; Chan et al., 
1981 J • 
Blood glucose concentrations during exercise are normal in 
haemodialysis patients despite significantly higher 
concentrations of insulin and glucagon throughout exercise 
[Kettner et al., 1984). Increased insulin concentrations 
inhibit lipolysis and stimulate muscle glucose uptake 
[Martin et al., 1981). However, this action of insulin may 
be impaired because of higher plasma concentrations of 
glucagon and parathyroid hormone [Eigler et al., 1976), both 
of which are elevated in patients receiving chronic 
haemodialysis [Bilbrey et al., 1974; Slatopolsky et al., 
1973] and which both impede glucose up t ake by musc l e. 
Furthermore, inhibition of the rate-limiting glycolytic 
enzyme, phosphofructokinase [Renner et al., 1972 ] , can 
further impair carbohydrate metabolism [Frolich et al., 
1978], which may then ultimately contribute to the 
associated weakness and fatigue [Nakoa et al., 1982] by 
reducing the maximum capacity for glycolytic energy 
production in the active muscles. 
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Artificially induced acidosis in healthy sedentary subjects 
during exercise causes early fatigue by decreasing the rate 
of rephosphorylation of ADP from glycolysis [Sahlin et al., 
1986]. Thus the metabolic acidosis present in end-stage 
renal failure [MacCleod J, 1977]and the reduced activity of 
the rate-limiting enzyme in the glycolytic pathway, 
phosphofructokinase [Renner et al., 1972; Metcoff et al., 
1978], may contribute to the early fatigue experienced by 
these patients during exercise. 
This argument is supported by the finding that the energy 
charge ratios in skeletal muscle at rest, as reflected by 
(ATP.ADP-1.AMp-1) ratios, were found to be significantly 
lower in haemodialysis patients compared to healthy 
sedentary controls [Cleminson et al., unpublished data]. 
This is possibly due to lower resting muscle phosphagen (ATP 
and PCr) concentrations in haemodialysis patients [DelCanale 
et al., 1986) or reduced skeletal muscle mitochondrial 
oxidative capacity. There is also a delayed recovery of 
muscle phosphocreatine concentrations during maximal 
exercise in haemodialysis patients [Ni s hida et al., 1991]. 
Two important steps in the metabolic pathway for the 
oxidative metabolism of long-chain fatty acids may also be 
impaired in the skeletal muscles of patients receiving 
chronic haemodialysis [Siami et al., 1991; Smogorzewski et 
al., 1988]. 
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Firstly the concentrations of L-carnitine, which plays an 
important role in mitochondrial beta-oxidation of long-chain 
fatty acids [Fritz, 1959] and is therefore important in 
energy production in skeletal muscle [Engel et al., 1973], 
are significantly lower in the skeletal muscles of patients 
with end-stage renal failure than in healthy controls 
[Bohmer et al., 1978; Leschke et al., 1983]. L-carnitine 
supplementation improved muscle endurance in a group of 
haemodialysis patients [Siami et al., 1991]. The mechanism 
explaining this effect is unclear. It is of interest that 
an abnormal distribution of lipid droplets in type I 
skeletal muscle fibres is considered to be the hallmark of 
the myopathy caused by carnitine deficiency [DiMauro et al., 
1980]; yet no such abnormality has been observed in skeletal 
muscle biopsies from patients with chronic renal failure 
[Ahonen, 1981). One possible explanation for the improved 
muscle endurance is that carnitine supplementation, in 
patients with end-stage renal failure undergoing maintenance 
haemodialysis, reduces muscle catabolism [Ahmad et al., 
1990] . 
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Secondly, fatty acid oxidation by the ske ~etal muscles of 
renal patients is further impaired as a result of elevated 
parathyroid hormone concentrations with reduction in the 
activity of carnitine palmitoyl transferase [Smogorzewski et 
al., 1988], a key enzyme essential for the transport of 
long-chain fatty acids into the mitochondrial matrix for 
beta-oxidation in muscle [Banks et al., 1979]. 
Lactate Production 
There is considerable disagreement in the literature 
regarding blood lactate concentrations during exercise in 
haemodialysis patients. 
Thus it has been suggested that blood lactate concentrations 
are either relatively high in haemodialysis patients when 
compared to healthy sedentary controls [Parrish et al., 
1981], or they are reduced during exercise [Nakoa et al., 
1982] or they are no different to concentrations measured in 
normal subjects, at similar work intensities [Kettner et 
al., 1984]. 
Parrish et al. (1981) reported elevated blood lactate 
concentrations in patients receiving chronic haemodialysis 
compared to normal healthy subjects at the same absolute 
exercise intensity. This should not be surprising since the 
renal patients were exercising at higher relative exercise 
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intensities as indicated by their significantly higher heart 
rates at those workloads (101 ± 13 vs 81 ± 12 beats). The 
intensity of work relative to the ind:vidual's maximal 
exercise capacity determines the b lcod i actate 
concentrations [Wasserman et al., 1973 ) . Thus studies which 
suggest that haemodialysis patients have elevated blood 
lactate concentrations during exercise may have reached 
incorrect conclusions if the relative exercise intensities 
for the renal patients and for the controls were not 
standardized. 
In contrast, other studies have suggested that the blood 
lactate response to exercise is diminished in patients with 
end-stage renal failure [Nakoa et al., 1982) and shows a 
similar response to that present i n pat i ents with McArdle's 
syndrome [Floyd et al., 197 4 J • Pat i ents with McArdle's 
syndrome have a greatly reduced exerc i se tolerance; in 
addition these patients are unable to mob i lize muscle 
glycogen to provide the energy for muscle contraction 
[Ganong, 1989, pg 243); hence blood lactate concentrations 
of patients with McArdle's syndrome do not rise 
significantly above resting concentrations. Rather the 
oxidation of blood-borne glucose and free fatty acids 
provide the major sources of energy [Braakhekke et al., 
1986]. This inability to utilize muscle glycogen results in 
its accumulation in the skeletal muscles of these patients 
[Ganong, 1989 pg 243). These twin characteristics of a 
reduced exercise tolerance and the accumulation of muscle 
glycogen have also been reported in haemodialysis patients 
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[Floyd et al., 1974; Nakoa et al., 1982]. However, at peak 
exercise, patients with end-stage renal failure have blood 
lactate concentrations which are significantly higher than 
their resting concentrations [Rbseler et al., 1980; Parrish 
et al., 1981; Kettner et al., 1984; Sagiv et al., 1991; 
Kempeneers et al., 1990]. 
Thus it is incorrect to equate the blood lactate response to 
exercise in patients with end-stage renal failure with that 
of patients with McArdle's syndrome. 
The blood lactate concentrations at rest and at similar 
relative intensities of submaximal exercise have been 
reported to be similar in control subjects and in those with 
end-stage renal failure receiving chronic haemodialysis 
[Kettner et al., 1984]. Peak blood lactate concentrations 
measured in healthy sedentary subjects are reported to be in 
the region of 10 - 15 mmo1.1-l [Harmansen et al., 1971], 
whereas peak blood lactate concentrations of haemodialysis 
patients are in the region of only 5.25 ± 1.67 mmo1.1-l 
[Rbseler et al., 1980; Sagiv et al., 1991]. These findings 
indicate that while blood lactate concentrations at rest and 
during submaximal exercise are similar in healthy controls 
and in patients with end-stage renal failure, peak 
concentrations are much lower in renal patients at the end 
of maximal exercise. A probable explanation for the lower 
peak blood lactate concentrations in these patients would be 
the much lower workloads that they achieve during maximal 
exercise. 
Therefore elevated blood lactate concentrations and the 
assoc i ated rise in hydrogen ions, which influence many of 
the processes involved in the transformation of chemical 
energy into mechanical work in healthy s ubj ects during 
maximal exercise [Sahlin, 1986], do not appear t o be the 
factor responsible for the low exercise t o l erance found in 
haemodialysis patients [Sagiv et al., 1991]. 
(ii) Neuromuscular Function 
Uraemic Neuropathy 
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Nervous system dysfunction in the form of a peripheral 
neuropathy, remains a major cause of disability in patients 
with end-stage renal failure [Fraser et al., 1988] and is 
present in about 65% of patients who are being treated with 
haemodialysis [Lindblom et al., 1985). The peripheral 
neuropathy is characterized by a mixed motor and sensory 
polyneuropathy, with a distribution that often results in 
weakness and wasting in the arms and legs [Nielsen, 1974]. 
Uraemic Myopathy 
There is a progressive loss of muscle strength, most 
pronounced in the legs, with advancing renal failure. This 
does not appear to improve with haemodialysis [Kettner, 
1982). It has been suggested that the underlying uraemia 
and acidaemia associated with end-stage renal failure or the 
treatment of end-stage renal failure is responsible for the 
muscle weakness [Floyd et al., 1974). Others have suggested 
that the myopathy is a result of the secondary hyper-
parathyroidism associated wi th end-stage renal failure 
[Frans et al., 1989]. 
Wasting and Maln utrition 
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Undernutrition depresses skeletal muscle function in healthy 
subjects [Chan et al., 1986]. Patients with renal failure, 
even when on haemodialysis, are poorly nourished as a result 
of anorexia from uraemic toxicity, medications, superimposed 
illness, psychological depression and re l atively unpalatable 
meals as well as oral and gastric abnormalities such as 
mucosa! ulceritis, oesophagitis, ascites and colonic 
obstructions [Massry et al, 1989; Harvey et al., 1980]. It 
is therefore not surprising that wasting and malnutr i tion 
are common in renal patients and most probably contr i bute to 
the muscle weakness in these patients [B l umenkrantz et al., 
1980; Berkelhammer et al., 1985; Kopple, 1983; Alvestrand et 
al., 1983]. 
The histopathology of this muscle weakness seen in renal 
failure is characterized by type II muscle fibre atrophy, 
identical to that observed in cachexia [Jennekens, 1981]. 
General Physical Deconditioning 
General physical deconditioning, not necessarily due to 
strict bed rest, is known to reduce exercise tolerance. 
After three weeks of strict bed rest, V02 max decreased by 
26% [Saltin et al., 1968]. Patients with end-stage renal 
failure generally lead extremely sedentary lifestyles. It 
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would not, therefore, be surprising if their inactivity also 
contributes to their poor exercise tolerance. Evidence for 
this suggestion is the increase in exercise tolerance 
associated with the introduction of exercise programmes of 
modest intensities [Shalom et al., 1984; Harter et al., 
1985; Carney et al., 1987]. 
(iii) Psychological factors 
Physical performance may be influenced by various 
psychological factors [Astrand et al., 1977]. Depression 
appears to be the most prevalent psychological reaction of 
patients undergoing chronic haemodialysis [Maher et al., 
1983; Levy, 1984]. Other problems include dependency, 
denial, stress, low quality of life, sexual dysfunction and 
fear of dying [Brown et al., 1984]. These psychosocial 
factors may adversely affect compliance to exercise 
programmes [Painter et al., 1987]. The possibility that 
these factors might also limit physical performance and 
habitual activity has not yet been investigated but needs to 
be considered. 
(iv) Conclusion 
In conclusion, patients with chronic renal failure 
undergoing chronic haemodialysis are severely limited in 










Failure to redistribute 
blood away from non-working 
tissue 
~ 


























N~ative ---= , • . 
- ----=- uraerrua 
inotropism 
blood flow - ; - Psychological 
' "'- Redue<d d=itry of o~gen / factors 
LOW EXERCISE TOLERANCE 
j( \ ' Decreased substrate Muscle weakness Inability to extract 
availability ,4 A ~ .,._ all available 













Mixed motor & sensory 
polyneuropathy 
Uraemia 








Figure 2.1 Possible factors limiting the exercise capacity of 
patients with end-stage renal failure receiving maintenance 
haemodialysis. 
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From the literature it appears as if opinion is divided into 
those who believe that the poor exercise tolerance of these 
patients results from central (cardiovascular ) abnormalities 
including reduced haemoglobin concentrations, arterial 
oxygen content, cardiac output, muscle oxygen extraction 
capabilities, and a compromised blood flow to the working 
muscles (see Fig 2.1); and those who argue for peripheral 
(skeletal muscle) limitations including impaired substrate 
utilization, muscle weakness caused by peripheral 
neuropathy, myopathy, malnutrition and general physical 
deconditioning. 
Recently Moore et al. (1993) have argued that impaired 
cardiovascular function together with anaemia and a reduced 
capacity for skeletal muscle oxygen extraction, limit the 
exercise tolerance of patients with end-stage renal failure 
receiving chronic haemodialysis. First they find that peak 
heart rates during maximum exercise are low in these 
patients, suggesting impaired central cardiovascular 
function; second even though arterial oxygen content was low 
because of the anaemia, the mixed venous oxygen content was 
the same, and the arterial-venous oxygen (A-V02) difference 
was less than values measured in other trained and sedentary 
subjects. When considered with the finding that EPO therapy 
does not always increase V02 peak and A - V02 difference 
during exercise, they argue that their second findings 
suggests that the muscles of patients with end-stage renal 
failure do not have a normal capacity for oxygen extraction. 
However Moore et al. (1993) have not shown that the reduced 
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heart rate response of these patients to exercise is due to 
a primary myocardial disease and secondly that the skeletal 
muscle contractile function of these patients is normal. On 
the contrary, skeletal muscle contractile function in 
patients with end-stage renal failure undergoing maintenance 
haemodialysis may be effected by conditions associated with 
the disease such as neuropathy [Kettner, 1982]; malnutrition 
(Berkelhammer et al., 1985]; secondary hyperparathyroidism 
(Smogorzewski et al., 1988]; and low carnitine muscle 
concentrations [Siami et al., 1991]. 
The emphasis of this thesis will be, therefore, to decide 
whether central cardiovascular function, or anaemia or 
muscle weakness causes patients with end-stage renal failure 
to terminate exercise at workloads well below those achieved 
by healthy controls. We planned to investigate the 
relationships between exercise tolerance, expressed as peak 
oxygen consumption, and variables relating to either 
skeletal muscle function or blood oxygen carrying capacity. 
Since the effects of EPO therapy on exercise tolerance 
appeared to support the anaemia argument, it was decided to 
study the effects and relationships that EPO had on exercise 
tolerance and skeletal muscle function. Furthermore, it was 
necessary to analyse the morphological features of their 
skeletal muscle to assess whether or not changes within the 
muscle structure may account for the muscle weakness and 
hence the severely impaired exercise tolerance found in 
these patients. Our final study was designed to determine 
the effects of beta-blocker therapy on peak heart rate 
values during maximal exercise in this group of patients. 
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CHAPTER 3 
ISOKINETIC MUSCLE STRENGTH PREDICTS MAXIMUM EXERCISE 
TOLERANCE IN RENAL PATIENTS RECEIVING CHRONIC HAEMOOIALYSIS 
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INTRODUCTION 
The poor exercise tolerance of patients with chronic renal 
failure receiving haemodialysis is believed to be due, at 
least in part, to the associated anaemia which limits oxygen 
delivery to skeletal muscles especially during maximal 
exercise [Painter et al., 1987; Zabetakis et al., 1982; 
Barnea et al., 1980]. Thus Zabetakis et al. (1982) found a 
significant correlation between blood haemoglobin 
concentration and peak oxygen consumption during maximal 
exercise in renal patients receiving chronic haemodialysis. 
However others have either failed to show a relationship 
between variables of blood oxygen carrying capacity and 
exercise tolerance [Barnea et a l ., 198 0; Lundin et al., 
1981] or any increase in physical performance subsequent to 
correction of haematocrit by blood transfusion [Sill et al., 
1972] or renal transplantation [Painter et al., 1986(a)]. 
Thus other factors such as altered peripheral metabolism, 
general physical deconditioning and ventricular dysfunction 
might better explain the impaired exercise tolerance of 
these patients [Painter et al., 1986(b); Lundin et al., 
1987]. 
A characteristic feature of chronic renal failure is the 
associated myopathy [Floyd et al., 1974]. It would be 
surprising if this myopathy was without effect on the 
exercise tolerance of patients receiving chronic 
haemodialysis. 
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To determine whether the maximal exercise tolerance of 
patients receiving chronic haemodialysis is limited by 
skeletal muscle factors, we performed conventional maximum 
exercise tests for measurement of peak oxygen consumption 
(VOz peak) in ten adult renal haemodialysis patients. In 
addition, isokinetic muscle strength was measured with an 
isokinetic cycle ergometer and a Cybex Isokinetic 
Dynamometer designed to maintain pedal-crank and angular 
velocity, respectively, constant at a pre-set level 
regardless of the torque generated by the subject [McCartney 
et al., 1983; Hislop et al., 1967]. Peak power produced 
during maximal cycling exercise of short (10 seconds) 
duration is considered to be independent of oxygen delivery 
and is therefore a measure of oxygen-independent skeletal 
muscle power (muscle contractility) [Oldridge et al., 1989; 
McCartney at al., 1989]. Further advantages in the use of 
isokinetic muscle testing is that this method allows the 
measurement of maximal torque over a wide range of 
contraction velocities and joint angles. In addition, the 
measurements are reproducible and the technique has been 
found to be safe in other groups of chronically ill patients 
[Oldridge et al., 1989; McCartney at al., 1989]. 
The purpose of this study was therefore to determine whether 
skeletal muscle function measured as isokinetic muscle 
strength or blood oxygen carrying capacity measured as total 
blood haemoglobin content, better predicted peak oxygen 
consumption and exercise tolerance in renal patients 
receiving chronic haemodialysis. 
MATERIALS ANO METHODS 
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Ten adult (7 female and 3 male) patients with chronic end-
stage renal failure receiving chronic haemodialysis 
volunteered for the study which had been approved by the 
Ethics and Research Committee of the Faculty of Medicine of 
the University of Cape Town. Each patient underwent a full 
medical examination by the senior renal consultant of the 
haemodialysis unit at Groote Schuur Hospital, before being 
accepted on to the study. The medical status of all 
patients accepted onto the programme was considered to be 
stable and all were considered capable of completing the 
study. Patients were randomly assigned to either of two 
groups. Group A first completed a maximum exercise test to 
exhaustion for measurement of V02 peak and exercise 
tolerance; in the following week they performed the 
isokinetic cycle test for measurement of peak isokinetic 
power at different cycling cadences. This sequence was 
reversed for Group B. 
After they had completed these tests, patients also 
performed maximal isokinetic exercise at two different 
contraction velocities on a Cybex II Isokinetic Dynarnometer 
(Cybex, Ronkonkoma, NY) with a Cybex Data Reduction 
computer. Only maximum isokinetic torque of the quadriceps 
muscle group from the dominant limb was recorded at both 
speeds. All testing was performed on a non-dialysis day, 
usually after the last haemodialysis treatment for that 
week. 
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Blood was drawn the day before the maximum exercise test for 
measurement of haemoglobin concentration and haematocrit 
using a model S-Plus Coulter counter (Coulter Electronics 
Inc., Miami, FL) in combination with an automatic dilution 
and mixing device for sample processing and a single-beam 
photometer for haemoglobin measurements [Brittin et al., 
1971] . 
The following day, patients reported to the laboratory for 
measurement of peak oxygen consumption using an 
electronically-calibrated stationary cycle ergometer. 
Patients cycled with a model No. 2766 counterbalanced head 
support holding a model No. 2700 Rudolph valve (both by Hans 
Rudolph Inc., Kansas City, KA). A nasal clip prevented 
nasal breathing. Expired air was sampled and analyzed as 
previously described [Noakes et al., 1990]. 
In brief, expired air was continuously sampled from a 15 1 
perspex mixing chamber to the pick-up heads of an Ametek 
oxygen analyzer model S-3Al (Applied Electro-Chemistry, 
Ametek Inc., Pittsburgh, Pennsylvania, USA), and an Ametek 
carbon dioxide analyzer model CD-3A (Applied Electro-
Chemistry, Ametek Inc., Pittsburgh, Pennsylvania, USA). 
Both analyzers were calibrated before and after each test 
using gases of known composition. Inspiratory volume was 
recorded with a Mijnhardt dry gas meter that had been 
calibrated against a Collins chain-compressed gasometer 
(Collins Inc., Braintree, Massachusetts, USA ) . Ra t es o f 
oxygen uptake (V02), carbon dioxide productioP- (VC02 ) and 
respiratory exchange ratios (RER ) were ca l cul a:ed each 
minute by an on-line computer (Apple) using locally 
developed software (A.R.T.) [Noakes et al., 1990) based on 
conventional equations [Jones Nl, 1988). Exercise heart 
rates were measured with a Lohmeier M607 ECG monitor 
(Munich, West Germany), using self-adhering e l ectrodes 
placed in the CMS position. Blood pressure was measured 
with a portable mercury sphygmomanometer. The cuff was 
placed on the arm that did not have the arter i o-venous 
fistula. Blood pressure was measured every two minutes 
during exercise. 
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Prior to commencement of the test, an intravenous cathe t er 
placement unit (Criticon; Tampa, FL, USA), was inserted into 
a subcutaneous forearm vein distal to the arterio-venous 
fistula and connected via pre-heparinized tubing to an Eyela 
Microtube pump (Rikakikai Co Ltd, Tokyo, Japan), which drew 
blood continuously at a rate of 2 ml.min-1. Blood samples 
were collected in test tubes containing 2 ml of 0.6N 
perchloric acid (PCA) every minute for 30 seconds during the 
test and at three minutes after stopping. Blood samples 
were centrifuged and the supernatant stored at -4oc pending 
analysis for lactate concentration by conventional 
techniques [Gutman et al., 1974). 
~· 
The exercise test protocol involved progress i ve increments 
in workrate until the patients voluntarily terminated the 
test. Patients were allowed a fo ur minute warm-up period 
during which they cycled against a workra t e o f O Watts. 
During this time they were familiarized wi th the apparatus 
used for collection of expired air samples. No measurements 
were recorded during this init i al warm-up period. 
Thereafter they exercised for a further two minutes at a 
workrate of O Watts after which the workrate was increased 
by 15 Watts every 2 minutes until exhaustion. Patients were 
asked to identify the nature of the symptoms they 
experienced at exhaustion. 
The isokinetic cycl e ergometer is a modified ergometer with 
a strengthened frame designed according t o that of McCartney 
et al., 1983. Special components include a 2.2kW DC 
electric motor (Femco 1605037), which serves as a dynamic 
load, a personal computer (Bondwell International, Hong 
Kong), and a locally designed Data Acquisition Unit (DAU) 
based on the Hitachi 6303 microprocessor and containing BK 
ROM and 48K RAM. 
Forces applied to the cranks are detected by four strain 
gauges. These strain gauges are calibrated by static 
loading with known weights on the left and right pedals 
which are locked in a forward facing horizontal position. 
Signals from the strain gauges are amplified by amplifiers 
located on the chain wheels. Peak signal values are 
recorded as peak torque during every cycle. The average 
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power per cycle is obtained by the trapezoidal rule. The 
work done per cycle is obtained directly from the result of 
the integral, that is the area under the torque.angle-1 
curve, whereas average power is obtained by dividi ng the 
work .done in a particular cycle by the duration of the 
cycle. 
Prior to testing the height of the saddle was adjusted to 
the preferred height for the cyclist. A position which 
allowed slight knee flexion when the pedal crank was angled 
vertically downward was used as the optimum saddle height 
[McCartney et al., 1983]. 
Each patient completed three 10 second maximal bouts of 
cycling at 70, 90 and 110 revolutions per minute. Before 
beginning each test, patients performed a brief warm-up at 
the required crank velocity to familiarize themselves with 
the ergometer. Patients rested for 1 minute after the warm-
up and for 2 minutes between the different tests. 
Patients also performed isokinetic exercise on the Cybex 
Isokinetic Dynamometer at limb contraction velocities of 60 
and 90 degrees.sec-1 [Hislop et al., 1967]. After they had 
performed 5 warm-up repetitions at each of the test speeds, 
patients completed six maximal repetitions at each speed. 
The warm-up was followed by a rest period of 1 minute. 
Patients rested for 2 minutes before beginning the warm-up 
at the next speed. 
Statistical methods 
Data are expressed as mean ±SD. Data for ventilation and 
blood lactate concentrations during exercise were fitted 
with the non-linear regression programme of the Institute 
for Scientific Information Graphpad (Philadelphia, 
Pennsylvania, USA). For all the other relevant data, 
straight lines were fitted by conventional least squares 
analyses. Statistical significance was assessed from the 
correlation coefficients (p <0.05). 
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RESULTS 
The anthropomorphic and haematological measurements in the 
10 patients are listed in Table 3.1. The mean duration of 
haemodialysis was 4.4 ± 3.8 (Mean ±SD) years. 
TABLE 3.1 ANTHROPOMORPHIC AND HAEMATOLOGICAL MEASUREMENTS 
AND CAUSE OF RENAL FAILURE IN 10 PATIENTS WITH END-STAGE 
RENAL FAILURE 
Sex Age Height Weight Cause of Duration Hb Hct 
of renal of 
(Yrs) (m) (kg) failure dialysis (%) 
(Yrs) (g.dl-1) (g) 
F 43 1.55 58.2 GN 3 8.3 26 
F 55 1. 59 57.0 HT 4 8.2 24 
F 47 1.64 56.8 PK 2 7.5 23 
M 26 1. 64 62.2 GN 5 7.5 21 
M 52 1. 60 61. 3 AN 8 7.8 23 
F 51 1. 52 51. 8 HT 1 8.6 26 
F 26 1. 64 62.1 GN 13 9.1 26 
F 37 1.55 45.1 HT 7 4.6 12 
M 17 1.68 59.4 SLE 0.8 8.6 25 
F 23 1. 51 44.8 GN 0.4 11. 0 30 
Mean 38 1. 60 56.5 4.4 8.1 24 
±SD ±13 ±0.06 ±6.4 ±3.8 ±1. 6 ±4.7 
Key: GN = glomerulonephritis; HT = hypertensive renal 
disease; PK = polycystic kidney; AN = analgesic 
nephropathy; 
SLE = systemic lupus erythematosis. 
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Glomerulonephritis was the cause of the chronic renal 
failure in 4 (40%) patients. Other causes of renal failure 
included hypertensive renal disease (30% ) and systemic lupus 
erythematosis, polycystic kidney and analgesic nephropathy 
(10% each). The mean haemoglobin concentration and 
haematocrit were 8.1 ± 1.6 g.d1-l and 24 ± 4.7,respectively. 
One female patient, aged 37 years, had a haemoglobin 
concentration of 4.6 g.d1-l and a haematocrit of 12%. The 
patient had concentrations of cytotoxic antibodies in excess 
of 50%. In view of this and because her condition was 
stable at the time of this study, it was considered 
advisable that she not receive unnecessary blood 
transfusions at that time. Despite this, she had received 7 
units of blood in the 12 months prior to the study. Despite 
having such a low haematocrit she completed all the testing 
procedures without any complications even though her V02 
peak was only 13.7 ml.kg-1.min-1, equal to that of another 
patient with a haematocrit of 24% and a haemoglobin content 
of 8.2 g.d1-l. The patient was included in the study 
because of her keen interest in participating and her 
initial medical examination which found her to be in a 
stable condition. 
Table 3.2 lists the cardiorespiratory and metabolic 
variables measured at rest and during peak exercise. 
Resting heart rate was elevated (98 ± 21 beats.min-1) and 
rose to 168 (± 12) beats.min-! during maximal exercise. 
Mean resting blood pressure was normal but 5 patients had 
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moderate hypertension (systolic blood pressure >145 nunHg or 
diastolic blood pressure >95 nunHg). Systolic blood pressure 
rose normally during exercise but diastolic pressure was 
elevated (>95 nunHg) in 8 patients. Individual values for 
the cardiorespiratory and metabolic parameters can be found 
in Table 3.3. 
TABLE 3.2. CARDIORESPIRATORY AND METABOLIC PARAMETERS AT 




Heart rate (beats .min-1) 98 ± 21 168 ± 12 
Blood pressure (mmHg) 
Systolic 135 ± 11* 173 ± 18 
Diastolic 89 ± 8* 107 ± 9 
Oxygen consumption (ml 02.kg-l.min-l) - 17.7 ± 3.6 
Oxygen pulse (ml.02-l.beat-l) 5.8 ± 1. 4 
Blood lactate concentration 1.1 ± 0.4 3.4 ± 0.9 
(mmol .1-l) 
RER (uni ts) 0.9 ± 0.1 1.1 ± 0.1 
Ventilation (l .min-1) 12.2 ± 1.9 37.3 ± 
14.6 
Maximum workrate (Watts) 70 ± 25 
Exercise duration (mins) 11 ± 3 
ABBREVIATIONS: RER=respiratory exchange ratio. 
Values are expressed as Mean± SD for n = 10 except* n = 9 
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Table 3.3. INDIVIDUAL CARDIORESPIRATORY; METABOLIC AND 
ISOKINETIC MUSCLE STRENGTH PARAMETERS AT REST AND DURING 
PEAK EXERCISE IN 10 PATIENTS WITH END-STAGE RENAL FAILURE 
1 2 3 4 5 6 7 8 9 10 
Heart rate 85 140 91 110 60 105 115 109 85 95 
153 180 145 169 186 168 200 160 170 180 
SBP 120 140 120 140 150 140 160 145 160 120 
150 180 150 180 210 180 180 210 170 180 
DBP 90 80 90 80 85 100 120 95 100 80 
105 120 90 110 110 115 110 110 110 110 
VO? 17.2 13.7 14.2 17.7 21. 3 18.5 19.0 13. 7 25.3 16.8 
Lactate 0. 71 0.99 1. 86 1. 39 1.17 1. 29 0.36 1. 46 0. 72 0.77 
1. 62 3.39 3.44 2.55 4.29 2.41 4.26 2.78 4.55 2.82 
RER 1. 00 1.12 1.12 1.27 1.25 1.10 1.16 0.98 1. 20 1.10 
Vent 9.5 11. 5 11 13.7 13.4 12.7 13. 0 9.5 * 15 . 7 
24.8 25.7 25.9 53.1 54.3 36.5 51. 9 14. 6 56.5 29.4 
Workrate 60 60 60 75 105 60 105 30 105 45 
Duration 10 10 10 11 16 10 15 6 16 8 
70 rpm 756 656 870 914 1228 813 1000 571 1129 756 
90 rpm 770 787 970 1081 1410 823 1134 605 1319 750 
110 rom 850 760 1051 1252 1454 825 1276 626 1342 716 
60 °.sec-l 59 69 75 74 120 73 87 59 98 55 
90 °.sec- 1 55 57 66 76 106 65 76 51 89 48 
Hb 8.3 8.2 7.5 7.5 7.8 8.6 9.1 4.6 8.6 11. 0 
Hct 26 24 23 21 23 26 26 12 25 30 
KEY: 1-lO=individual patients (3,4,9=males };Heart rate 
(beats.min-1); SBP=Systolic Blood Pressure (mmHg}; 
DBP=Diastolic Blood Pressure (mmHg}; V02=oxygen consumption 
(ml.02 k~-1.min-1); Lactate=blood lactate concentration 
(mmol.1- }; RER=Respiratory Exchange Ratio; Vent=Ventilation 
(l.min-1); Workrate=maximal workrate achieved (Watts); 
Duration=Exercise duration (minutes); 70, 90, 110= Speeds 
tested on isokinetic cycle (Watts); 60, 90=Speeds tested on 
Cybex dynamometer (ft.lbs); Hb=haemoglobin (g.dl-1); 
Hct=haematocrit (%} .; *=missing value. 
NOTE: Were 2 numbers appear together in a single cell the 
top number refers to resting value whereas the bottom number 
denotes the peak recorded value. 
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The peak oxygen consumption (17.7 ± 3.6 ml 02.kg-l.min-l) 
was achieved at low peak rates of vent · lation (37.3 ± 14.6 
l.min-1), at low peak blood lactate co~centrations (3.4 ± 
0.9 mmo1.1-l ) and at very low peak workloads (70 ± 25 
Watts), but at elevated peak respirato~y exchange ratios of 
1.1 ± 0.1. 
Figure 3.1 shows the changes in oxygen consumption, heart 
rate, ventilation and blood lactate co~centrations measured 
during the progressive exercise test. The linear and curve-
fitting equations which describe the data are depicted on 
the Figure. The data are for all 10 patients for the first 
6 minutes, for 9-7 patients up to 10 minutes, and for 3 
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Fi gure 3. 1 : Changes in oxygen consumption, heart rate, 
vent ilation and blood lactate concentrations during 
progressive exercise to exhaustion in 10 patients with end-
stage renal fa i lure. Note the absence of a plateau in 
oxygen consumption with increasing workrate (exercise 
duration ) . 
Oxygen consumption rose linearly with increasing exercise 
duration (r2 = 0.99) and in none of the patients did a 
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plateau in oxygen consumption develop [Noakes, 1988]. Blood 
lactate concentrations rose as an exponential function of 
exercise duration as previously described [Hughson et a l ., 
1981; Dennis et al., 1991). Ventilation a l so increased as 
an exponential function of exercise duration (r2 = 0.99 ) . 
All patients terminated exercise with blood lactate 
concentrations below 4 mmo1.1-l. Reasons for terminating 
the test include leg fatigue (n = 4), general fatigue (n = 
3), dry mouth (n = 2) and thigh cramps (n = 1). 
Peak isokinetic power measured on the cyc l e at 70,90 and 110 
r.min-1 was 869 ± 205, 965 ± 265 and 1015 ± 297 Watts 
respectively. Peak isokinetic torque measured using the 
Cybex dynamometer at 60 and 90 degrees.sec-1 was 128 ± 27 
and 117 ± 28 ft.lbs respectively. The changes in isoki netic 
strength with increasing crank or angular velocity was not 
significant (p>0.05). 
Correlation analyses were performed between peak oxygen 
consumption (ml02.kg-l.min-l) and variables relating either 
to oxygen carrying capacity and transport (haemoglobin 
concentration,haematocrit; peak heart rate, respectively) or 
to isokinetic muscle strength. Table 3.4 shows that there 
was no significant correlation between peak oxygen 
consumption and variables relating to blood oxygen carrying 
capacity. However a significant correlation was found 
between peak oxygen consumption and isokinetic muscle 
strength measured with either the isokinetic cycle ergometer 
(r = 0.73 tor= 0.84; p <0.05 to p<0.01) or the Cybex 
Isokinetic Dynamometer (r = 0.66 to 0.68; p<0.05). 
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TABLE 3.4 CORRELATION COEFFICIENTS FOR PEAK OXYGEN 
CONSUMPTION AND VARIABLES RELATING TO EITHER ISOKINETIC 
SKELETAL MUSCLE FUNCTION OR BLOOD OXYGEN CARRYING CAPACITY 
AND TRANSPORT 
Variable 
Peak isokinetic power 
Isokinetic cycle (Watts) 
at 70 r.min-1 
at 90 r.min-1 
at 110 r.min-1 
Cybex dynamometer (ft.lbs) 
at 60°.sec-1 
at 90°.sec-1 
Peak lactate concentration (mmo1.1-l) 
Blood Oxygen Carrying Capacity 
Haematocrit (%) 
Haemoglobin concentration (g.dl-1) 
Blood Oxygen Transport 
Peak Heart Rate 























The possibility that muscle weakness may explain the poor 
exercise tolerance of patients with end-s t age renal failure 
receiving chronic haemodialysis has been suggested by 
previous authors [Painter et al., 1986(b ) ; Lundin et al., 
1987], but direct evidence for this proposal has been 
lacking. 
The first important finding of this study was to show that 
the patients terminated exercise with low peak heart rates 
and low peak ventilation rates, at low peak blood lactate 
concentrations and with low peak values for oxygen 
consumption (Figure 3.1). Furthermore a p l ateau in oxygen 
consumption was not identified in any pat ient [Noakes, 
1988]. Had the anaemia been a significant component of the 
impaired exercise tolerance of renal haemodialysis patients, 
one might have expected higher, that is near maximal values 
for peak ventilation, peak heart rate and peak blood lactate 
concentrations [Lundin et al., 1987]. The low peak blood 
lactate concentrations as also measured by others [Barnea et 
al., 1980; Lundin et al., 1987] argue against the early 
onset of "anaerobic" metabolism as a cause of fatigue in 
these patients [Lundin et al., 1987]. It needs to be 
emphasized that the haematocrit and haemoglobin 
concentrations as well as the peak oxygen consumptions and 
peak achieved workloads measured in this study are similar 
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to those reported by others [Painter et al., 1986(b); Shalom 
et al., 1984; Roseler et al., 1980]. 
More convincing evidence that the anaemia could not explain 
the impaired exercise tolerance of these patients, was the 
failure to show any significant correlation between 
variables relating to oxygen carrying capacity or 
transport(haematocrit and haemoglobin concentration; peak 
heart rate, respectively) and either oxygen consumption or 
peak achieved workrate (Table 3.4). However, due to the 
small sample size statistical significance may be present 
but not observed. In contrast, there was a strong 
correlation between peak isokinetic muscle strength measured 
with either the isokinetic bicycle or the Cybex Isokinetic 
Dynamometer and peak oxygen consumption, exercise duration, 
peak ventilation and peak blood lactate concentrations. 
These findings therefore confirm the suggestion made by 
Robertson et al. (1990), that muscle strength contributes 
significantly to the poor exercise tolerance in patients 
receiving chronic haemodialysis. Interestingly, the recent 
study of Lipkin et al. (1988), also found a significant 
correlation between isokinetic muscle power and peak oxygen 
consumption in patients with congestive heart failure. The 
correlation coefficient (r 0.86) was similar to that found 
in this study (r = 0.84). Furthermore the correlations 
found in this study were almost identical to those reported 
by Robertson et al. (1990), viz. (r = 0.68 vs r = 0.64), 
when V02 peak was correlated with isokinetic quadriceps 
muscle strength. 
St.M-fARY 
Patients with end-stage renal failure receiving chronic 
haemodialysis have impaired exercise tolerance. 
To distinguish between a central cardiorespiratory and a 
peripheral skeletal muscular origin for thi s fatigue, we 
measured exercise performance and peak oxygen consumption 
during a maximum exercise test in 10 patients receiving 
chronic haemodialysis. · Skeletal muscle function was 
measured with an isokinetic cycle ergometer and a Cybex II 
isokinetic dynamometer. 
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Peak rates of oxygen consumption (17.7 ± 3.6 (Mean ±SD) ml 
02.kg-l.min-l ) , blood lactate concentrations (3 .4 ± 0.9 
mmo1.1-l), peak heart rates (168 ± 12 beat s.min-1) and rates 
of ventilation (37.3 ± 14.6 L.min-1) were low but 
respiratory exchange ratios (1.1 ± 0.1) were compatible with 
maximal effort. 
There was a significant correlation between isokinetic 
muscle strength and V02 peak, exercise duration, peak 
ventilation and peak blood lactate concentrations but not 
between haemoglobin concentration or hematocrit and these 
variables. 
Therefore in renal haemodialysis patients, muscle 
contractile function may be one of several important 
contributing factors, present in renal failure, responsible 
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A number of recent studies have shown that recombinant hum.an 
erythropoietin (EPO), which partially corrects the anaemia 
in patients with end-stage renal failure receiving chronic 
haemodialysis, also increases their capacity for maximal 
exercise [Robertson et al., 1990; Mayer et al., 1988; Mayer 
et al 1989; MacDougall et al., 1990; Bocker et al., 1988; 
Canadian Erythropoietin Study Group, 1990; Graf et al., 
1987; Lundin et al., 1991). Since V02 peak also increased 
significantly after EPO treatment in these studies, some 
authors have concluded that EPO increases the exercise 
tolerance of these patients by increasing their capacity for 
oxygen delivery to the active muscles during maximal 
exercise [Mayer et al., 1988; Mayer et al, 1989; Graf et 
al., 1987). Hence, they interpret these findings as 
evidence for a central (cardiovascular) limitation for 
exercise tolerance in these patients. 
However if, as suggested in Chapter 3, skeletal muscle 
oxygen deficiency does not limit the exercise tolerance of 
these patients even when they are anaemic, then an increased 
potential for oxygen delivery to the active muscles 
following correction of the anaemia, might not solely 
explain why EPO treatment increases the exercise tolerance 
of these patients. 
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Accordingly, in this study, we have performed maximal 
exercise tests before and after 3 months of EPO t herapy, in 
a group of patients with end-stage renal failure receiving 
chronic haemodialysis. We wished to determine whether EPO 
therapy alters physiological variables during s ubmaximal and 
maximal exercise. In addition, we studied the effect of EPO 
therapy on skeletal muscle contractile function measured 
with an isokinetic dynamometer. 
Changes in these variables were compared with a control 
group of patients with end-stage renal failure who did not 
receive EPO therapy during the same experimental period. 
MATERIALS AND METHODS 
Nine adult patients receiving chronic haemodialysis 
volunteered for this study, which had been approved by the 
Ethics and Research Committee of the Faculty of Medicine of 
the University of Cape Town. Each patient underwent a full 
medical examination conducted by a renal physician and 
signed an informed consent form prior to testing. All were 
on stable medical regimens, diets and haemodialysis 
programmes involving a 12 hr.week-1 haemodialysis regimen. 
Fresenius A 2008 C haemodialysis machines (Fresenius, 
Germany) were used, with the haemodialysis concentrate 
containing acetate. PCR (Protein Clearance Ratio) and KT.v-
1 (K = constant; T = duration of haemodialysis; and V = 
blood volume of patient) values were not yet being used to 
assess adequacy of dialysis, however the clinical condition 
of the patients were used to monitor their dialysis 
regimens. Furthermore, the haemodialysis regimens of the 
patients who received EPO did not change appreciably during 
or after the study. 
At the time of doing the study EPO had been introduced into 
South Africa only on a trial basis and this was one of the 
first studies to use EPO in this country. Only sufficient 
EPO was made available for 5 patients. One of the patients 
put onto EPO did not wish to be part of our study. 
Therefore our experimental group was limited to 4 patients. 
All testing was done the day after patients had received 
their last haemodialysis treatment for the week. The 
initial test was performed prior to commencement of EPO 
treatment and the second test three months later. The 
control group received normal medical care during this 3 
month period but were not given EPO. 
Selection to the experimental or control groups was made 
purely on medical grounds by the renal physicians caring for 
the patients and was not influenced by the requirements of 
this study. The lower initial haemoglobin concentrations of 
the group who received EPO therapy is an expected 
consequence of this selection. 
The methods used to determine haemoglobin concentration, 
peak oxygen consumption, exercising blood lactate 
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concentrations and isokinetic muscle strength were the same 
as those described in the study reported i n Chapter 3. 
In brief, haemoglobin concentra t ion was det ermi ned t he day 
before t he patients underwent the maxima: exercise test. 
The next day the patients reported t o t he exercise 
laboratory for measurement of peak oxygen consumption using 
an electronically calibrated cycle ergometer. The exercise 
test involved continuous progressive increments in workrate 
until the patient voluntarily terminated the test. The test 
started at O Watts and increased by 15 Watts every 2 
minutes. Samples for measurement of blood lactate 
concentration were collected at rest and 30 seconds before 
the end of each workrate. 
All nine patients completed the maximum exercise test; one 
patient commenced EPO treatment before the initial muscle 
strength testing could be scheduled. Blood lactate 
concentrations during the maximum exercise test were not 
analyzed in one patient due to inadequate blood samples 
being collected during the test. 
During the week following the maximal exercise test, 
patients performed maximal isokinetic exercise on the Cybex 
Isokinetic Dynamometer (Lum.ex Inc., Ronkonkoma, NY) for 
determination of peak quadriceps isokinetic torque 
development at limb contraction velocities of 45, 60, 90 and 
180 degrees.second-!. The data were reduced and analyzed as 
previously described in Chapter 3. 
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Statistical methods 
Group data for each variable are expressed as mean ~SD. A 
one-sided paired sample Students' t-test was used to compare 
values at the start and termination of t he study. Data for 
blood lactate concentrations during exercise were fitted 
with the non-linear regression programme of the Institute 
for Scientific Information Graph Pad (Philadelphia, PA). 
Straight lines were fitted by conventional least squares 
analyses for the oxygen consumption data. Statistical 
significance was established at the level of p< 0.025 
because of the small sample size. 
RESULTS 
The personal characteristics of the patients are listed in 
Table 4.1. That the division into control and experimental 
groups occurred according to gender was beyond the control 
of the experimenters and is justified by the higher 
haemoglobin concentrations of the control patients (Table 
4.2). However there is no evidence that gender influences 
the physiological responses to exercise or the adaptations 
to training in these patients [Kempeneers et al., 1990]. 
Only one patient (Case 4 in the experimental group) was on 
anti-hypertensive medication; initially the treatment was 
metoprolol 100 mg per day but this was changed to verapamil 
120 mg tds after EPO therapy had been started. The extent 
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to which this change in medication effected our results was 
unfortunately impossible to assess. 
None of the measured variables changed in the control group 
during the 3 month period (Table 4.2 and 4.3). Samples from 
the control group for blooq lactate analysis in the follow-
up study were inadvertently discarded before analysis could 
be performed. 
In contrast to the control group, haemoglobin concentrations 
were significantly increased (p <0.01) following the 3 
months of EPO therapy whereas serum ferritin concentrations 
did not change (Table 4.4 and 4.5 ) . Peak achieved workrate 
(p <0.025), exercise duration (p <0.025 ) , peak oxygen 
consumption (p <0.025) and peak venti lation (p <0.025) all 
increased significantly during the maximum exercise test 
after EPO treatment (Table 4.4 and 4.5). Resting heart rate 
decreased with therapy but peak heart rate, resting and peak 
systolic and diastolic blood pressures, peak and resting 
blood lactate concentrations and peak respiratory exchange 
ratios (RER) were not altered (Table 4.4 and 4.5). All 
patients complained that leg fatigue was the predominant 
symptom terminating exercise. 
TABLE 4.1. PERSONAL CHARACTERISTICS AND CAUSES OF RENAL 
FAILURE IN NINE PATIENTS WITH END-STAGE RENAL FAILURE 
RECEIVING CHRONIC HAEMODIALYSIS 
PATIENT SEX AGE WEIGHT CAUSE OF DURATION 
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ON 
(YR) (KG) FAILURE DIALYSIS (YR) 
( 1) EXPERIMENTAL GROUP 
1 M 41 58 CGN 2 
2 M 47 64 CGN 4 
3 M 48 48 CGN 6 
4 M 18 44 BCN 6 
Mean 38.5 53.3 4.5 
(± SD) (14) (9) (2) 
( 2) CONTROL GROUP 
5 F 55 57 HT 4 
6 F 26 62 CGN 13 
7 F 22 48 RN 8 
8 F 47 57 PKD 2 
9 F 43 58 CGN 3 
Mean 38.6 56.4 6.0 
(± SD) ( 14) ( 5. 1) ( 4. 5) 
KEY: Abbreviations CGN = Chronic Glomerulonephritis; 
BCN = Bilateral Cortical Necrosis; HT = Hypertensive renal 
disease; PKD = Polycystic kidney disease; RN = Reflux 
nephritis. 
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TABLE 4.2. HAEMATOLOGICAL, MAXIMAL EXERCISE AND ISOKINETIC 
MUSCLE TEST RESULTS BEFORE AND AFTER EPO TREATMENT IN 5 
CONTROL PATIENTS WITH CHRONIC RENAL FAILURE NOT RECEIVING 
EPO TREATMENT DURING A 3 MONTH PERIOD 
Haemoglobin (g.dL-1) 
Maximal Exercise Test: 
Initia l 
7.9 ± 0.9 
Peak achieved workrate (Watts) 70 ± 20 
Duration (mins) 
Peak V02 (ml 02.kg-l.min-l) 
Peak ventilation (L.min-1) 
Peak RER 
Heart rate: Rest (b.min-1) 
Max 
Systolic BP: Rest (mmHg) 
Max 
Lactate: Rest (mmol.1-l) 
Max 
Isokinetic Muscle Function: 
10.8 ± 2.4 
15.8 ± 2.2 
33.0 ± 11.6 
1.14 ± 0.1 
110 ± 21 
170 ± 22 
132 ± 19 
158 ± 22 
0.97 ± 0.55 
3.0 ± 1.1 




76 ± 15 
69 ± 12 
61 ± 10 
46 ± 7 
Three months later 
7.0 ± 1.4 
66 ± 13 
10.2 ± 2.2 
15.2 ± 1.2 
38.7 ± 14.9 
1.17 ± 0.1 
106 ± 21 
158 ± 17 
132 ± 24 
164 ± 29 
79 ± 17 
76 ± 15 
61 ± 10 
50 ± 6 
KEY: Abbreviations EPO = Recombinant Human Erythropoietin; 
V02 = Oxygen Consumption; BP= Blood Pressure. 
66 
TABLE 4.3. INDIVIDUAL HAEMATOLOGICAL, MAXIMAL EXERCISE AND 
ISOKINETIC MUSCLE TEST RESULTS BEFORE AND AFTER EPO 
TREATMENT IN 5 CONTROL PATIENTS WITH CHRONIC RENAL FAILURE 
NOT RECEIVING EPO TREATMENT DURING A 3 MONTH PERIOD 
1 2 3 4 5 
Haemoglobin 8.8 9.1 6.6 7.5 8.3 
8.1 6.3 5.0 8.2 7.7 
Workrate 60 60 105 60 60 
60 60 90 60 60 
V02 13.7 14.8 19 14.2 17.2 
15.7 15.9 16.5 14.6 13.4 
Duration 10 9 15 10 10 
10 9 14 9 9 
Ventilation 25.7 36.7 51 25.9 24.8 
28.6 39.7 62. 6 38.6 24 
RER 1.12 1.28 1.16 1.12 1. 00 
1.15 1.19 1.32 1.15 1. 06 
Resting Heart 140 90 115 91 113 
rate 1 35 88 123 90 96 
Peak Heart 180 174 200 145 153 
rate 170 165 168 160 128 
Rest SBP 140 110 16 0 120 130 
140 120 170 110 120 
Peak SBP 180 130 180 150 150 
200 150 190 140 140 
Rest Lactate 0.99 0.92 0.36 1. 86 0.71 
* * * * * 
Peak Lactate 3.39 2.08 4.26 3.44 1. 62 
* * * * * 
45 74 79 96 78 54 
88 75 103 73 58 
60 69 69 87 67 52 
86 67 95 72 59 
90 57 61 76 61 48 
76 53 83 69 55 
180 50 38 54 49 40 
56 40 54 52 48 
!IE(: 1-5=Irrli.v.i.d.Bl µrt:i.alts; Haarogl.d::rin (g.dl.-1); ~ wxkrate(W:!.tts); ~ aK}g:!1 
a::rs.nptim (nil.Oi.kg-1.min-1) ; ~ du:aticn (minxes) ; 'knti.latim=pee "81tilatim 
(l.min-1); R:R=peak re;pi.r.at.ory exx::hcn;Je ratio; Heart i::ate (beet:s.min-1); ~c blcxx:i 
pressure ~) ; L:w:tat.e=bloc: lactate cr:n::mtrat:im (nnol.r 1, ; 45, a),~' 1~ t.est:e::i en ~ 
isckireti.c d}n:rrareter (degrees. sec-1); ~ "81.te 
NJIE: ne tcp rumer in each aill. refers to tre initial test an tre 1xtt.an rumer refers to tre 
test 3 mrths later 
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TABLE 4.4. GROUP HAEMATOLOGICAL, MAXIMAL EXERCISE AND 
ISOKINETIC MUSCLE TEST RESULTS BEFORE AND AFTER EPO 
TREATMENT IN 4 PATIENTS WITH CHRONIC RENAL FAILURE RECEIVING 
EPO THERAPY 
Before EPO therapy After EPO therapy 
Haemoglobin (g.dL-1) 
Serum ferritin (ng.mL-1) 
Maximal Exercise Test: 
5.4 ± 0 .8 
2910 ± 4604 
Peak achieved workrate (Watts) 79 ± 12 
Duration (mins) 
Peak V02 (ml 02.kg-l.min-l) 
Peak ventilation (L.min-1) 
Peak RER 
Heart rate: Rest (b.min-1) 
Max 
Systolic BP: Rest (mmHg) 
Max 
Lactate: Rest (mmol.L-1) 
0.12 
Max 
Isokinetic Muscle Function: 
11.8 ± 1.6 
20.2 ± 5.8 
36.8 ± 7.8 
1.1 ± 0 . 05 
91 ± 16 
161 ± 20 
146 ± 29 
173 ± 33 
1. 77 ± 0 . 34 
3.46 ± 0.50 





108 ± 9 
105 ± 9 
98 ± 5 
65 ± 2 
9.9 ± 0.4* 
2538 ± 4267 
109 ± 19** 
16.0 ± 2.7** 
27.3 ± 8.5** 
44.7 ± 9.1** 
1. 1 ± 0. 03 
69 ± 9 
155 ± 12 
133 ± 29 
175 ± 45 
0.95 ± 
5.50 ± 1.4 
12 5 ± 5* 
121 ± 6* 
114 ± 9* 
78 ± 2* 
KEY: Abbreviations EPO = Recombinant Human Erythropoietin; 
V02 = Oxygen Consumption; BP= Blood Pressure. 
Significance* p <0.01; ** p <0.025. 
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TABLE 4.5. INDIVIDUAL HAEMATOLOGICAL, MAXIMAL EXERCISE AND 
ISOKINETIC MUSCLE TEST RESULTS BEFORE AND AFTER EPO 
TREATMENT IN 4 PATIENTS WITH CHRONIC RENAL FAILURE RECEIVING 
EPO THERAPY 
1 2 3 4 
Haemoglobin 5.3 5.0 4.6 6.7 
10.8 9.8 9.3 9.9 
Workrate 60 90 90 75 
90 135 120 90 
V02 19.4 29.8 17.3 14.5 
24.0 41.2 26.6 17.9 
Duration 9 13 13 12 
13 20 17 14 
Ventilation 34.7 50.1 31.2 30.8 
37.1 60.2 42.2 39.4 
RER 1. 08 1. 07 1.18 1.05 
1. 08 1. 08 1.16 1.10 
Resting Heart 90 115 88 70 
rate 79 58 62 75 
Peak Heart 169 187 154 132 
rate 159 159 165 135 
Rest SBP 120 190 120 155 
90 160 120 160 
Peak SBP 140 200 140 170 
120 190 150 240 
Rest Lactate 2.45 1. 34 1. 52 * 
0.93 0.75 0.89 * 
Peak Lactate 3.43 4.35 2.62 * 
4.76 8.21 3.61 * 
45 * 106 89 110 
* 111 108 120 
60 * 109 86 103 
* 116 107 112 
90 * 99 80 95 
* 108 96 110 
180 * 67 63 66 
* 70 71 56 
KEY: l-4=Individual patients; Haemoglobin (g.dl-1); 
Workrate=Peak workrate(Watts); V02=Peak oxygen consumption 
(ml02.kg-l.min-l); Duration=exercise duration (minutes); 
Ventilation=peak ventilation (l.min-l)i RER=peak respiratory 
exchange ratio; Heart rate (beats.min- ); SBP=Systolic blood 
pressure (mmHg); Lactate=blood lactate concentration 
(mmo1.1-l); 45,60,90,180=Speeds tested on Cybex isokinetic 
dynamometer (degrees.sec-1); *=missing value 
NOTE: The top number in each cell refers to the initial test 
and the bottom number refers to the test 3 months later 
Figure 4.1 shows changes in oxygen consumption (A ) , heart 
rate (B), ventilation (C) and blood lactate concentrations 
(D) with increasing workrate before and after treatment in 
the experimental patients. 
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Before EPO therapy, one patient reached 60 Watts, one 75 
Watts and two, 90 Watts. After treatment two patients 
reached 90 Watts, one 120 Watts an d one, 135 Watts. As a 
result of the higher maximal work l oads achieved by all 
patients, the peak oxygen consumpt ion increased by 26 + 5%. 
None of the patients demonstrated a 'plateau' [Kempeneers et 
al, 1990; Noakes TD, 1988] in peak oxygen consumption, 
before or after EPO treatment. In addition, oxygen 
consumption at all submaximal workl oads (0 - 75 Watts) were 
essentially identical in both tes t s (Figure 4.1). 
Heart rate increased linearly with increasing workrate in 
experimental patients both before and after EPO therapy and 
was reduced by approximately 20 beats.min-1 at all workloads 
(Figure 4.1, line B). 
Ventilation volume increased as a curvilinear function of 
work rate and was marginally lower at each workrate after 
EPO treatment (Figure 4.1, line C) . 
Blood lactate concentrations also rose as a curvilinear 
function of increasing workrate (Figure 4.1, line D). There 
was a trend for these concentrations to be reduced at rest 
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and during submaximal exercise and peak concentrations to be 
increased, but these differences failed to reach statistical 
significance. 
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Figure 4.1: Changes in oxygen consumption (V02) (top left), 
heart rate (top right), ventilation volume (bottom left) and 
blood lactate concentrations (bottom right) during 
progressive exercise to exhaustion in 4 patients with end-
stage renal failure before and after EPO therapy. 
Peak isokinetic strength increased significantly (p <0.01) 
at all testing velocities following EPO treatment (Table 
4.3) but was unchanged in the control patients (Table 4.2). 
Patients in the experimental group had higher isokinetic 
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muscle strength and higher V02 peak before and, especially, 
after EPO therapy. We believe the initial higher values to 
be a gender-related difference. 
TABLE 4.4. CORRELATION COEFFICIENTS FOR PEAK OXYGEN 
CONSUMPTION AND VARIABLES RELATING TO EITHER ISOKINETIC 
MUSCLE FUNCTION OR BLOOD OXYGEN CARRYING CAPACITY 
Variable 
Isokinetic Muscle Strength 
at 45 0 .sec-1 
at 60 0 .sec-1 
at 90 0 .sec-1 
at 180 0 .sec-1 
Blood Oxygen Carrying Capacity 
haemoglobin concentration 






KEY: ABBREVIATIONS deg.sec-1 = degrees per second; NS= not 
significant. 
As in the previous study [Chapter 3], there were significant 
correlations between isokinetic muscle strength and V02 
peak, but not between haemoglobin content and V02 peak 
(Table 4.4). Figure 4.2 shows a significant linear 
regression (r = 0.62; p <0.02) between V02 peak and peak 
torque as measured at 90 °.sec-1. The correlations and the 
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regression were performed on all patients, before and after 
the 3 month trial period. 
-0, 40 • ~ ......_ 
r 0.62 C: 
•r-11 
E p < 0.02 ......_ 30 r-t 0 
E -
N 





50 100 150 
PEAK TOROlE fKP/sec (ft·lbs) 
Figure 4.2: Relationship between peak oxygen consumption 
(V02 peak) and peak torque at 90 °.sec-1 using both groups 
results, before and after the 3 month period. The open and 
closed circles are for the EPO group, before and after 
treatment, respectively. The open and closed squares are 
for the control group, before and after the 3 month period, 
respectively. 
Although not specifically measured, all patients in the 
experimental group indicated that since starting therapy, 
they coped better with activities of daily living such as 
walking and stair climbing. 
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DISCUSSI~ 
Partial correction with EPO therapy of the anaemia 
experienced by patients with end-stage renal failure has 
been shown to increase their exercise to l erance (Robertson 
et al., 1990; Lundin et al., 1991). It would seem logical 
to presume that this results from enhanced oxygen delivery 
to the exercising muscles [Mayer et al., 1988; Mayer et al., 
1989; Graf et al., 1987). 
However Robertson et al. (1990) concluded that the increased 
exercise tolerance resulting from EPO therapy was less than 
might be expected from an equivalent elevation of 
haemoglobin concentrations in patients with anaemia of other 
causes. They concluded that: "These comparisons suggest 
that some as yet unidentified factor bes i des transport of 
oxygen to tissues is a major determinant of the maximal 
exercise performance of the haemodialysis patients.". As 
those authors, like us, found a significant correlation (r 
0.64) between isometric muscle strength and peak oxygen 
consumption, they concluded that muscle weakness may be 
responsible for the low V02 peak measurements and poor 
exercise tolerance of haemodialysis patients even after 
partial correction of their anaemia. Support for this 
interpretation comes from a number of other studies and is 
confirmed by the findings of the current investigation. 
As early as 1987, Lundin et al. (1987) observed that 
patients with end-stage renal failure terminated maximal 
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exercise because of leg fatigue and with only small changes 
from base-line values for arterial pH and lactate 
concentrations. They concluded that "early, unexplained 
musc l e fatigue" which was not due to "muscle hypoxia" caused 
these patients to terminate exercise well before "estimated 
maximum cardiac output and muscle 02 levels" had been 
reached. In their most recent study, these workers [Lundin 
et al., 1991] reported that there was no correlation between 
the increase in circulating haemoglobin concentration and 
the V02 peak following EPO therapy. Metra et al. (1991), 
have also reported the same observation. 
Subsequently essentially the same findings in both renal 
transplant recipients who were not anaemic [Kempeneers et 
al., 1990] were reported from this laboratory. Furthermore, 
in Chapter 3, anaemic patients with end-stage renal failure 
showed the same response. In patients from both t hese 
groups, peak exercise terminated without evidence for a 
central cardiovascular limitation to exercise [Noakes, 1988] 
which might have been shown by a ' plateau' in oxygen 
consumption with increasing workrate, near maximal heart 
rates and rates of ventilation, as well as markedly elevated 
peak blood lactate concentrations. 
Furthermore, as confirmed by the findings of Robertson et 
al. (1990), we also found that isokinetic muscle strength 
predicted peak oxygen consumption in anaemic patients with 
chronic renal failure receiving chronic haemodialysis 
[Chapter 3]. 
Thus, like Robertson et al. (1990 ) , we have concluded that 
muscle strength probably limits the exercise tolerance of 
renal patients both before [Chapter 3) and after renal 
transplantation [Kempeneers et al., 1990) and that the 
important effect of exercise training, at least in renal 
transplant recipients, may be to increase muscle strength 
[Kempeneers et al., 1990). 
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The findings of this study are therefore in agreement with 
these conclusions. For the patients in this study also 
terminated exercise, both before and after EPO treatment, 
with low heart rates, low rates of ventilation and low blood 
lactate concentrations (Table 4.3 ) and without evidence for 
a 'plateau' in oxygen consumption (Figure 4.1). 
Furthermore, oxygen consumption at submaximal workloads was 
unaltered by EPO therapy (Figure 4.1). Blood lactate 
concentrations were reduced both at rest and during 
submaximal exercise (Figure 4.2), but this effect was not 
statistically significant. These findings mirror those 
reported by Robertson et al. (1990). 
Thus the ability of the patients to continue exercising at 
those workloads at which they had terminated exercise prior 
to EPO treatment, could not have been due to enhanced oxygen 
delivery to the active muscles after EPO therapy as absolute 
oxygen consumption at that workrate had not changed. 
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Accordingly, we conclude that the reason why EPO therapy 
enhanced the exercise tolerance of these patients was not 
simply a result of increased haemoglobin content causing 
enhanced oxygen delivery to the active muscle during 
exercise. Moreover, we suggest that associated with the 
increase in haemoglobin concentration was a significant 
improvement in muscle strength which allowed the patients to 
tolerate higher workloads. Consequently by achieving higher 
peak workloads their V02 peak increased simultaneously. 
There are three possible explanations for the increased 
isokinetic muscle strength measured in these patients after 
EPO therapy. 
First, the increased levels of habitual daily activity 
reported by all patients after EPO treatment may have 
produced a muscle training effect. This does not, however, 
explain why EPO therapy should have increased the levels of 
habitual physical activity in these patients in the first 
place. 
Alternatively, the anaemia may cause a regulated alteration 
in skeletal muscle contractile function by mechanisms other 
than a reduction in oxygen delivery to the muscles. An 
analogous situation may occur in cardiac patients in whom 
skeletal muscle dysfunction may occur and is probably the 
factor limiting their exercise tolerance [Lipkin et al., 
1988; Massie et al., 1987(a); Massie et al., 1987(b)]. 
Possibly chronic anaemia also impairs skeletal muscle 
function which recovers only when the anaemia is wholly or 
partially corrected. 
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However this cannot be the complete answer because some 
researchers have been unable to find significant 
correlations between changes in exercise tolerance in 
anaemic patients with end-stage renal failure following 
acute changes in haemoglobin concentrations following blood 
transfusions [Sill et al., 1972] or renal transplantation 
[Painter et al., 1986(a)]. 
Paradoxically, those studies which show that changes in 
total haemoglobin content predict changes in exercise 
tolerance in renal patients [Mayer et al., 1988; Mayer et 
al., 1989; Clyne et al., 1989] are also compatible with the 
postulate that anaemia causes impaired muscle contractile 
function. Thus they cannot be interpreted simply as 
evidence that the correction of the anaemia acts exclusively 
by reducing skeletal muscle hypoxia during exercise. 
A third factor which may be influenced by EPO therapy and 
which may contribute to the low exercise tolerance of these 
patients, is the chronic acidosis characteristic of end-
stage renal failure. Sutton et al. (1981) found that 
experimentally-induced metabolic acidosis significantly 
reduces peak blood lactate concentrations and exercise 
performance during maximal exercise. Metabolic acidosis has 
also been shown to increase muscle catabolism [Mitch et al., 
1989). Possibly the metabolic acidosis associated with 
chronic renal failure may also be partially responsible for 
the chronically-impaired skeletal muscle function in these 
patients. 
Unfortunately we did not study the effect of EPO therapy on 
the acid-base balance of these patients during exercise. We 
did, however, note a trend for blood lactate concentrations 
to be lower after EPO therapy (Figure 4.1) suggesting that 
acid-base status may well have been influenced, possibly by 
the increased buffering capacity of the larger red cell mass 
after EPO therapy. 
In summary, this study confirms that the exercise tolerance 
of patients with end-stage renal failure increases following 
partial correction of their anaemia with EPO therapy 
[Robertson et al., 1990; Mayer et al., 1989; MacDougall et 
al., 1990; Bocker et al., 1988; Canadian Erythropoietin 
Study Group, 1990; Graf et al., 1987; Lundin et al., 1991]. 
However we show that the mechanism for this effect may not 
be that EPO simply enhances oxygen delivery to the active 
muscles during exercise by increasing the circulating 
haemoglobin concentration. 
Rather we confirm the findings of Robertson et al., 1990 
that EPO therapy is associated with enhanced skeletal muscle 
function in these patients. This could result either from 
increased levels of daily physical activity in these 
patients following partial correction of their anaemia; or 
possibly because EPO therapy in some ways enhances the 
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impaired skeletal muscle contractile function that results 
either from the primary disease or from the associated 
anaemia. One possible way in which EPO therapy may enhance 
skeletal muscle function is the proposed anabolic effect 
[Zehnter et al., 1988) supported by findings of increased 
muscle protein content during one year's treatment with EPO 
[Barany et al., 1991). Unfortunately dietary protein intake 
and the effects of EPO on those intakes were not measured in 
the present study. Future studies should include dietary 
evaluations. The finding that circulating haemoglobin 
concentration is not related to either V02 peak or skeletal 
isokinetic muscle strength raises questions about its value 
as the single measure on which to base decisions regarding 
the necessity of starting EPO therapy. Perhaps a measure of 
exercise tolerance should be included in this evaluation. 
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Sunmary 
The mechanisms by which treatment with EPO enhances the 
exercise tolerance of patients with end-stage renal failure 
receiving chronic haemodialysis is not known. 
We therefore compared changes in exercise tolerance and peak 
oxygen consumption during a maximum exercise test, and 
isokinetic skeletal muscle function in 4 experimental 
patients and 5 controls immediately before, and after 3 
months during which the experimental group received EPO. 
Haemoglobin concentrations rose significantly with treatment 
(5.4 ± 0.8 vs 9.9 ± 0.4 [mean ±SD] g.dL-1; p <0.02) as did 
peak rates of oxygen consumption (20.2 ± 5.8 vs 27.3 ± 8.5 
ml o2 .kg-1.min-1; p <0.025). Neither oxygen consumption 
during submaximal exercise nor blood lactate concentrations 
at exhaustion were influenced by EPO treatment, although 
blood lactate concentrations at rest and during submaximal 
exercise were reduced. Peak quadriceps isokinetic muscle 
strength at three different contraction velocities improved 
significantly (p <0.01). None of these variables changed in 
the control group. 
Identical rates of oxygen consumption during submaximal 
exercise both before and after treatment, low and unchanged 
peak blood lactate concentrations and the absence of a 
'plateau' in oxygen consumption during maximal exercise 
indicate that peripheral oxygen supply was not solely 
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responsible for limiting maximal exercise either before or 
after treatment with EPO. The observation that submaximal 
as well as maximal heart rates were lower following partial 
correction of their anaemia, does not necessarily indicate 
better peripheral oxygen blood flow. Rather, we suggest 
that stroke volume may have increased as a result of the 
correction of anaemia. Future investigations should measure 
variables such as stroke volume to test this hypothesis. 
Therefore, the improved exercise tolerance of renal patients 
who receive EPO therapy does not appear to be solely due to 
reversal of muscle hypoxia which develops during maximal 
exercise but could result from an effect of EPO therapy on 
skeletal muscle contractile function. Confirmation of this 
hypothesis would require larger sample sizes; assessment of 
nutritional status, especially protein intake, before and 
after EPO therapy; direct measurement of muscular oxygen 
delivery and utilization during exercise; as well as changes 
in acid-base status. 
CHAPTER 5 
MORPHOLOGICAL FEATURES OF THE MYOPATHY ASSOCIATED WITH 
CHRONIC RENAL FAILURE 
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INTRODUCTION 
As early as 1974, Floyd et al. (1974), showed that the 
skeletal muscles of renal patients receivi ng chronic 
haemodialysis showed significant electromyographic and 
morphological abnormalities but without evidence of 
neuropathic changes. 
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Our earlier studies found that skeletal muscle weakness is 
an important factor limiting the maximum exercise tolerance 
of patients who have either undergone renal transplantation 
[Kempeneers et al., 1990] or who are receiving chronic 
haemodialysis [Chapter 3] or therapy with erythropoietin 
(EPO) [Chapter 4]. Skeletal muscle biopsies performed in a 
group of physically-trained renal transplant recipients 
showed an unexpected predominance of Type II skeletal muscle 
fibres and a reduced skeletal muscle oxidative capacity 
(Q02 ) [Kempeneers et al., 1990] but more detailed 
histological studies were not performed. 
This chapter describes the histological findings in skeletal 
muscle biopsies of patients undergoing haemodialysis for 
end-stage renal failure. The exercise tolerance of these 
patients was shown to be limited by skeletal muscle weakness 
[Chapter 3]. 
MATERIALS AND METHODS 
Eight of the ten patients receiving haemodialysis for end-
stage renal failure studied in Chapter 3 consented to have 
skeletal muscle biopsies performed. Characteristics of 
these patients was their very low peak exercise tolerance 
measured as the peak oxygen consumption (V02 peak). All 
patients were on a 12 hour per week dialysis programme and 
their dialysate contained acetate. The research protocol 
had been approved by the Research and Ethics Committee of 
the Faculty of Medicine of the University of Cape Town. 
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A piece of muscle was removed from the vastus lateralis 
muscle under local anesthesia according to the open biopsy 
method described by Dubowitz et al. (1985). The biopsy 
fragment was divided into four sections: one piece for 
routine light microscopy was frozen in iso-pentane cooled 
in liquid nitrogen; the section for histology was cut on a 
standard cryostat freezing microtome; several fragments were 
fixed in buffered gluteraldehyde and prepared in the usual 
manner for transmission electron microscopy; the remainder 
was used for the measurement of muscle oxidative capacity 
(Q02) using the technique described by Ivy et al. (1980), as 
modified in this laboratory [Lambert et al., 1989]. 
Blood samples were drawn routinely from these patients prior 
to their dialysis and analysed according to conventional 
techniques for haemoglobin concentration and haematocrit and 
serum or plasma concentrations of total protein, albumin, 
urea, creatinine, calcium, inorganic phospha t e and 
bicarbonate. Serum parathormone concent ra tions were 
determined by radio-immune assay using N-tac t PTH IRMA 
(Incstar Corporation, Stillwater, Minnesota, 55082 ) . 
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Control samples for muscle histological analysis were 
obtained from 7 athletic subjects undergoing arthroscopic 
knee surgery and from another 5 subjects who were untrained 
but otherwise healthy. Muscle biopsy sampl es were collected 
using a closed biopsy technique, but were prepared and 
analyzed using the identical techniques that were used for 
the patient samples. 
Habitual dietary intake was calculated from a 2-day dietary 
record in which the weight of all foodstuffs ingested were 
reported. Dietary analysis was performed using the Floro 
Diet Data Programme (Durban, South Africa ) . 
RESULTS 
The physical charact~ristics of the patients are listed in 
Table 5.1. Patients had been receiving haemodialysis for a 
mean of 5 years; their renal failure had been caused by two 
diseases; glomerulonephritis and hypertensive renal disease. 
Table 5.2 lists biochemical, haematological and nutritional 
data in the patients with chronic renal failure. Blood 
samples were collected immediately prior to dialysis; hence 
serum urea, creatinine and inorganic phosphate 
concentrations were elevated whereas the plasma bicarbonate 
concentration was reduced. Haematocrit, haemoglobin 
concentration and serum total protein and albumin 
concentrations were within the normal range. Serum 
parathormone concentrations were elevated above the normal 
range of 10-55 pg.m1-l in 6 of the 8 patients. 
Dietary analysis in 7 patients showed a mean protein intake 
of 0.96 (± 0.17) g.kg-1.day-l; slightly less than the 
recommended intake of 1.2 g.kg-1.day-l. Mean daily energy 
intake of 27.8 (± 6.5) Kcal.kg-1.day-l was also less than 
the recommended intake of 35 Kcal.kg-1.day-l. Mean dietary 
composition of 48 (± 7)% carbohydrate, 37 (± 8)% fat and 15 
(± 2)% protein was within the expected range [Table 5.2). 
Muscle oxidative capacity (Q02) (19.5 ± 5.7 µl o2 .g-l.hr-l: 
Mean± SD) was not different from values previously reported 
in physically trained renal transplant recipients (21.3 ± 
6.6 µl 02.g-l.hr-l) [Kempeneers et al., 1990], but was 
significantly lower (p <0.05) than values measured in a 
group of trained female endurance athletes (28.3 ± 7.1 µl 
02. g-1. hr-1) . 
TABLE 5 .1. PATIENT CHARACTERISTICS 
Sex Age Ht Wt Duration of Cause of Serum 
(Yrs) (m) (kg) dialysis renal failure PTH 
(Yrs) cone* 
(pg .ml -1) 
F 23 1.51 44.8 0.3 GN 550.7 
F 37 1. 55 45.1 7 HT 164.2 
F 51 1. 52 51. 8 1 HT 101. 0 
M 26 1. 64 62.2 5 GN 675.5 
F 43 1. 55 58.2 3 GN 340.6 
F 55 1.59 57.0 4 HT 8.4 
F 22 1. 49 48.0 8 GN 172.1 
F 26 1. 64 62.1 13 GN 22.1 
Mean 34 1.56 53. 7 5 254.0 
(±SD) (12) (0.06) (7.2) ( 4) (24.6) 
Key: GN = glomerulonephritis 
HT = hypertensive renal disease 
PTH = parathyroid hormone 
cone= concentration 
* Normal range 10-55 pg.m1-l 
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TABLE 5.2 PRE-DIALYSIS BIOCHEMICAL, HAEMATOLOGICAL AND 
NUTRITIONAL MEASUREMENTS IN 8 PATIENTS WITH CHRONIC RENAL 
FAILURE RECEIVING CHRONIC HAEMODIALYSIS 
Case No. 
Variable 1 2 3 4 5 6 7 8 Mean ±SD 
Hb 11. 0 4.6 8.6 7.5 8.3 8.2 6.6 9.1 8.0 ±1. 9 
(g.dL-1) 
Hct 30 17 26 21 26 24 18 26 24 ±5 
(%) 
Total 68 65 53 66 65 63 65 56 ±23 
protein 
(g.dL-1) 
Albumin 46 39 44 37 39 43 40 41 41 ±3 
(g.dL-1) 
Urea 24 28 28 29 23 24 25 23 26 ±2 
(rnmol. L -1) 
Creat. 1320 1206 1267 1637 1159 1294 1285 1408 1322 ±147 
(µmol.L-1) 
Calcium 2.3 2.1 2.3 2.2 2.3 2.5 2.2 2.4 2.3 ±0.1 
(rnmol. L -1) 
Inorg. 1. 6 1.1 2.2 2.7 1. 3 1. 8 2.1 1. 8 1. 8 ±0.5 
phosphate 
(rnmol. L -1) 
PTH 551 676 341 8 101 172 164 22 254 ±246 
(pg.ml-1 ) 
Bicarb. 19 21 14 18 18 15 16 17 ±2 
(rnmol. l -1) 
Energy 1163 1480 1627 1676 1400 807 2086 1463 ±405 
Intake* 
(Kcal. day-1) 
Energy 26 30 25 32 27 17 38 28 ±7 
Intake 
(Kcal.kg-1.day-1) 
Protein 0.9 1. 0 1. 0 0.8 1.1 0.7 1.2 1.0 ±0.2 
Intake 
(g.kg-1.day-1) 
% CHO 47 53 51 40 38 58 50 48 ±7 
intake 
% Fat 39 33 32 49 45 25 35 37 ±8 
intake 
% Protein 14 14 17 11 17 17 15 15 ±2 
intake 
Key: Hb=haemoglobin; Hct=haematocrit; Total protein=serum 
total protein; Albumin=serum albumin; Creat.=creatinine; 
Inorg.=inorganic; PTH=serum parathormone; *=total daily 
energy intake; CHO=carbohydrate. 
Note: All blood measures are from samples drawn immediately 
prior to dialysis. 
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Light microscopy revealed that all of the patients had 
atrophied type II fibres (6-62%) while 2 of the patients 
also had hypertrophy of the type I fibres (51% in patient 6; 
Table 5.3). The significant changes present were fibre 
splitting, internalized nuclei, nuclear knots, moth-eaten 
fibres, fibre degeneration, increased content of lipid 
droplets and fibre-type grouping (Table 5.3). Myosin ATPase 
stains on frozen tissue revealed a mean Type I fibre size of 
61.2 µm (± 11.8 µm) and a mean Type II fibre size of 46.7 µm 
(± 11.4 µm) (Table 5.4). Two patients had significant Type 
II fibre atrophy (mean diameter less than 40 µm - Dubowitz 
et al., 1985). The mean Type II muscle fibre% was 67 (± 
12) (Table 5.4). Two patients displayed Type II fibre 
predominance (% greater than 80% [Dubowitz et al., 1985]. 
Table 5.4 lists the morphometric skeletal muscle evaluation 
of the control subjects, all of which are in the normal 
range. 
Electron microscopy of the muscle samples from 10 of the 
control subjects had normal ultrastructural features (Figure 
5.1); the myocytes contained smoothly outlined nuclei with 
evenly dispersed chromatin and nuclei of normal size. The 
mitochondria were regular in shape and size and small 
subsarcolemmal aggregates were occasionally seen. The 
myofibrils were aligned and the sarcomeric units showed 
regular A, Z, H, Mand I banding. Glycogen granules were 
evenly dispersed throughout the cells and no large 
accumulations were present. The lipid droplets were of 
normal size and distribution and were usually situated near 
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the mitochondria. The sarcoplasmic membranes and overlying 
basement membranes were continuous and evenly contoured. 
The muscle sample from one control subject revealed foci of 
myofibrillar loss and the occasional swollen mitochondrion, 
while another had numerous lipid droplets, subsarcolemmal 
mitochondrial aggregates and increased glycogen content 
(Table 5.3). 
Figure 5.1: Control muscle showing regular myofibrillar 
arrangement, aligned sarcomeric units, normal mitochondira 
and evenly dispersed glycogen granules (x 9 750). 
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TABLE 5.3 MORPHOLOGICAL SKELETAL MUSCLE EVALUATION IN 8 
PATIENTS WITH END-STAGE RENAL FAILURE AND 12 CONTROLS. 
Case No. Light Microscopy 
1. Fibre atrophy (60%), fibre 
splitting, internal nuclei, 
nuclear chains, moth-eaten 
fibres, lipid increased, 
fibre grouping. 
2. Type II fibre atrophy (62%), 
fibre necrosis, severe fibre 
splitting, numerous internal 
nuclei, nuclear chains, 
nuclear knots, moth-eaten 
fibres, increased lipid, 
fibre grouping. 
3. Type II fibre atrophy (14%), 
regenerating fibres, fibre 
splitting, internal nuclei, 
moth-eaten fibres. 
4. Type II fibre atrophy (32%), 
fibre splitting, internal 
nuclei, nuclear chains, fibre 
grouping. 
5. Type II fibre atrophy (36%), 
fibre splitting, numerous 
internal nuclei, nuclear 
chains and knots, fibre 
grouping. 
Electron Microscopy 




stacking and splitting. 













regation. Scalloped fibres. 




hypertrophy and splitting. 
Multinucleated and central 
nuclei. 
Swollen and disrupted mito-
chondria. Subsarcolemmal 




nucleated. Excessive myelin 
figures. 
6. Type II fibre atrophy (5-10%),Swollen and disrupted mito-
hypertrophied Type I and II chondria. Subsarcolemmal 
fibres, myofibre degeneration, glycogen aggregation. 
fibre splitting, numerous Excessive fibre splitting. 
internal nuclei, cytoplasmic Z-band streaming. Multi-
inclusion, moth-eaten fibres. nucleated. Increased 
dilation of the sarco-
plasmic reticulum. 
7. Type II fibre atrophy {20%), 
fibre necrosis, inflammatory 
cells, internal nuclei, 
lipid increased. 
8. Type II fibre atrophy (6%) 
and hypertrophied Type I 
fibres, fibre splitting, 
internal nuclei, nuclear 
chains and knots. Lipid 
increased. 
Controls 
1. Internal nuclei, lipid 
increase, subsarcolernmal 
mitochondrial clusters. 










Fibril l ar bodies. 






nucleated and central 
nuclei. 
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Numerous lipid droplets. 
Increased glycogen in some 
fibres. Subsarcolemmal 
mitochondrial aggregates. 
Foci of myofibrillar loss. 
Occasional swollen mito-
chondria. 
Control subjects 3-12 did not show any abnormalities on 
electronmicroscopy. 
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TABLE 5.4 MORPHOMETRIC SKELETAL MUSCLE EVALUATION IN 8 
PATIENTS WITH END-STAGE FAILURE AND 12 CONTROL SUBJECTS 
Case No. Fibre Size (µm) % Type II 
Fibres 
Type I Type II 
Patients 
1. 60.9 ± 11.2 36.7 ± 9.8** 64 
2. 55.4 ± 8.3 44.3 ± 10.0 79* 
3. 50.8 ± 10.6 44.4 ± 12.7 68 
4. 80.5 ± 14.0 58.9 ± 14.8 68 
5. 60.8 ± 10.1 49.3 ± 11. 4 69 
6. 53.8 ± 10.3 48.9 ± 10.2 52 
7. 64.8 ± 8.9 36.5 ± 10.5** 85* 
8 . 65.2 ± 15.5 56.4 ± 11. 8 50 
Controls 
1. 74.1 ± 10.6 77.0 ± 12.0 58 
2. 62.7 ± 11.1 47.3 ± 14.1 65 
3. 73.3 ± 13.0 79.6 ± 14.8 57 
4. 81.1 ± 15.5 75.3 ± 15.6 67 
5. 60.2 ± 10.0 65.3 ± 9.9 44 
6. 62.4 ± 10.1 68. 3 ± 8.9 38 
7 . 68.5 ± 10.4 72.1 ± 13.1 43 
8. 70.4 ± 10.9 80.0 ± 14.3 39 
9. 57.2 ± 11. 3 58.1 ± 8.2 38 
10. 65.0 ± 11. 5 69.8 ± 10.0 49 
11. 57.6 ± 10.1 62. 4 ± 9.8 72 
12. 59.6 ± 8.0 56.9 ± 9.1 67 
Controls 1-5 were sedentary whereas controls 6-12 were 
athletic males, aged between 20-30 years, who were 
undergoing athroscopic knee surgery. 
Key: * Type II fibre predominance 
** Significant Type II fibre atrophy. 
In contrast, electron microscopy of myocytes from the renal 
patients revealed mitochondrial changes, Z-band degeneration 
and loss of myofilaments in all patients (Table 5.3). These 
changes which were more widespread and severe than those 
found in 2 of the control subjects, appeared to be 
progressive with some cells being more severely affected 
than others. Where evidence of severe mitochondrial damage 
was found, the myofilamentous changes were also more marked. 
Mitochondria showed a spectrum of changes. These included 
the formation of either paracrystalline or angular electron 
dense (Figures 5.2 and 5.3) intra-mitochondrial inclusions. 
Bizarre branching mitochondria were also seen; frequently 
these were arranged at right angles to the sarcomeres 
(Figure 5.4). Extensive myofilament and Z-band lysis with 
associated swollen and disintegrated mitochondria containing 
occasional myelin figures and loss of christae was also a 
common feature (Figure 5.5). Myocytes showing evidence of 
mitochondrial damage showed accumulat i on of glycogen 
granules (Figure 5.6). 
Myofibre changes varied from Z-band streaming to loss of z-
bands and myofilaments (Figure 5.7). The severity of the 
myofibre loss varied in proportion to the severity of the 
mitochondrial damage. Thus, where severe loss of 
myofilaments was found, mitochondria were severely swollen 
or degenerate. 
Evidence for muscle regeneration was present. Regenerated 
myocytes showed multiple nuclei with characteristic 
margination of chromatin and prominent nucleoli (Figure 
5.8). Occasional multi-nucleated primitive cells revealed 
their myoblastic nature by the presence of scanty 
myofilaments and irregular primitive Z-bands (Figure 5.9). 
The degenerative and regenerative changes were frequently 
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found side by side, indicating an ongoing process of damage 
and repair. 
Figure 5.2 A mitochondrion containing an elongated 
"paracrystalline-like" inclusion (arrow) (x 54 675). 
Figure 5.3. Mitochondria showing angula~, e l ectron dense 
inclusions (arrows) (x48 600) . 
96 
Figure 5.4. Large branching, p l eomorph i c mitochondria which 
also transverse the myofilaments (x 19 2 0 0 ) . 
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Figure 5.5. Severe myofilament and Z-band dissolution is 
evident. The mitochondria are swollen, disrupted and 
contain myelin whorls and a paucity of christae (arrows) (x 
10 430). 
Figure 5 . 6. Intermyofibrillar and large sub-sarcolemmal 
glycogen (g) aggregates are present . Z-band lysis (arrows) 
is also evident (x 6 825) . 
9S 
Figure 5.7. Myofibrillar disorganization with Z-band 
streaming. Z-band and myofilament loss is also present (x 
22 400) ~ 
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figure 5.8. A myocyte with several tandem nuclei containing 
prominent nucleoli (x 6 825). 
101 
Figure 5.9. A multinucleated myofibroblast displaying large 
nucleoli, irregular myofilament arrangements and small, 
immature and randomly orientated Z-band (arrows) (x 8 94 0) . 
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DISCUSSION 
In a previous study from this laboratory [Kempeneers et al., 
1990] the skeletal muscles of renal transplant recipients 
were shown to have a preponderance of Type II fibres with 
low oxidative capacity. Patients with congestive heart 
failure also show this preponderance [Lipkin et al., 1988]. 
The present study found these changes in only 2 of the 8 
patients receiving chronic haemodialysis. Further, muscle 
fibre size and distribution was not different from the 
normal population [Doriguzzi et al., 1984]. Skeletal muscle 
oxidative capacity was reduced compared to values measured 
in athletes but was not lower than values measured in 
physically trained renal transplant patients [Kempeneers et 
al., 1990] suggesting that this abnormality may not be 
reversed by either renal transplantation or exercise 
training. However this specific technique provides a 
relatively less sensitive measure of skeletal muscle 
oxidative capacity. Perhaps more sensitive measures 
including analysis of specific oxidative enzyme activities, 
may be required to accurately quantify the extent of any 
abnormality in skeletal muscle oxidative capacity in these 
patients and its response to renal transplantation or 
exercise training, or both. 
However the important contribution of this study is to show 
significant changes on light and electron microscopy in 
muscle samples taken from these patients. Light microscopic 
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changes included fibre splitting, internalized nuclei, fibre 
degeneration and regeneration, increased content of lipid 
droplets and fibre-type grouping. Electronrn.icroscopy 
revealed mitochondrial and myofilamentous changes in these 
patients (Table 5.3); changes that were not present in 10 of 
the 12 control subjects sampled under identical conditions. 
In particular, there was extensive myofilament and Z-band 
lysis (Figure 5.7), glycogen accumulation (Figure 5.6) and 
evidence of regeneration (Figures 5.8 and 5.9). 
Mitochondria with bizarre shapes (Figure 5.4), with 
inclusions (Figures 5.2 and 5.3) and loss of christae 
(Figure 5.5) were common. Abnormalities present in 2 of the 
control subjects were of a minor nature (Table 5.3). 
Many of the mitochondrial changes seen are non-specific and 
their morphology does not offer a clue to their 
pathogenicity. Similar changes have been described in 
patients with intermittent claudication (Teravainen et al., 
1977) and in tourniquet-induced ischaemia {Mortimer et al., 
Unpublished observations). However, mitochondria with 
branching forms and unusual orientation across the 
sarcomeres have not to our knowledge, been reported 
previously. 
Some of the morphological abnormalities reported in this 
paper were also found by Floyd et al. (1974). They found 
Type II fibre atrophy and non-specific degenerative changes 
including numerous foci of Z-band degeneration; small foci 
of myofibre necrosis; complex lipid vacuoles, and sub-
sarcolemmal mitochondrial aggregates. 
Similarly the increase in muscle glycoge~ content reported 
in this study has also been found in soEe (Floyd et al., 
1974; Nakao et al., 1982] but not all previous studies 
[Bergstrom et al., 1969]. 
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The explanation for these changes are not clear. Floyd et 
al. (1974), suggested that many factors including acidosis, 
abnormalities in vitamin D metabolism or in serum calcium 
concentrations, or renal haemodialysis itself may explain 
these abnormalities. Elevated serum parathyroid hormone 
(PTH) concentrations have been shown to enhance muscle 
proteolysis, to impair muscle oxidative capacity 
[Smorgorzewski et al., 1988] and to be associated with 
intra-mitochondrial inclusions [Ghadially FN, 1975] similar 
to those seen in this study. However, not all of the 
patients in this study had elevated serU!!l PTH concentrations 
(Table 5.1), although all had mitochondrial abnormalities. 
Other possible explanations include prolonged inactivity and 
dietary deficiencies in particular, an inadequate protein or 
calorie intake, or inappropriate haemodialysis schedules. 
However the majority of inactive controls in this study did 
not show any of these abnormalities (Table 5.3) nor have 
such abnormalities been reported in healthy but inactive 
subjects [Dubowitz et al., 1985]. In addition, protein 
105 
intake was adequate and serum total protein and albumin 
concentrations were normal in these patients suggesting that 
severe dietary deficiencies were not present in the total 
group of patients. Furthermore, blood biochemical measures 
taken immediately prior to dialysis (Table 5.2 ) and on which 
decisions regarding the dialysis schedule are based, were 
within the norms for this Renal Unit. 
How might these morphological abnormalities explain the 
impaired exercise tolerance of these patients? Exercise in 
patients with congestive heart failure is associated with an 
abnormally large reduction in phosphocreatine (PCr ) 
concentrations with an increased intracellular acidosis 
[Massie et al., 1987). The same abnormalities have recently 
been reported in patients with end-stage renal failure 
[Nishida et al., 1991) who also showed delayed recovery of 
muscle pH after exercise. These changes are compatible with 
an impaired capacity for oxidative metabolism which 
presumably results from the mitochondrial abnormalities 
reported in this study. 
Despite this finding that muscle pH falls more rapidly 
during low intensity exercise in patients with end-stage 
renal failure, this cannot be the sole reason why their 
exercise tolerance is impaired. For patients with end-stage 
renal failure who have either undergone renal 
transplantation [Kempeneers et al., 1990) or who are 
receiving chronic haemodialysis [Chapter 3), or who have 
also received EPO therapy [Chapter 4] all terminate maximum 
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exercise at low blood lactate concentrations. Nor do they 
develop even a mild acidosis during maximal exercise [Lundin 
et al., 1987). This indicates that the impaired skeletal 
muscle oxidative capacity measured in both groups, and the 
mitochondrial abnormalities identified ir. these renal 
haemodialysis patients, does not limit their exercise 
tolerance by increasing their reliance on "anaerobic" 
glycolysis or with the development of a marked acidosis 
[Lundin et al.,1987). Hence the exact mechanism whereby the 
mitochondrial and myofilamentous abnormalities identified 
in these patients, might impair their exercise tolerance 
remains to be established. 
In summary, this study establishes that the skeletal muscles 
of patients receiving chronic haemodialysis show specific 
abnormalities, in particular multiple mitochondrial 
abnormalities, excessive glycogen content and marked 
myofilamentous loss. Further, the damage appears to be 
ongoing with degenerative changes being found in fibres 
adjacent to others showing evidence of regeneration. 
Although this study cannot offer an explanation for the 
pathogenicity of the myopathy of renal failure, we have 
demonstrated morphological and biochemical changes in the 
muscle which may be sufficiently severe to account for the 
muscle weakness and severely impaired exercise tolerance 
found in all these patients [Painter et al., 1986(b); Barnea 
et al., 1980; Gutman et al., 1981; Lundin et al., 1987; 
Kempeneers et al., (1990); Chapter 3; Chapter 4]. 
S~Y 
Chapter 3 suggested that impaired function of skeletal 
muscle limits the exercise tolerance of patients with end-
stage renal failure who are maintained on haemodialysis. 
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To study the morphology of the condition, muscle biopsies 
were performed on eight patients with renal failure-
associated myopathy. Control samples were taken from seven 
healthy athletes undergoing knee surgery and from five 
otherwise healthy but untrained subjects. 
Tissues were examined by routine light and transmission 
electron microscopy. Histochemical staining of frozen 
sections for ATPase and quantitative computer-assisted 
morphometry of the fibre type and size was performed. Mean 
(~SD) size for Type I fibres in patients was 61.2 (~11.8 µm) 
while Type II fibres measured 46.7 (~11.4 µm). The mean 
Type II fibre% was 67 (+12%). These values are within the 
normal population range and were not different from 
controls. Significant changes were found on light 
microscopy of patient samples. These included fibre 
splitting, internalized nuclei, nuclear knots, moth-eaten 
fibres, fibre degeneration and regeneration, increased 
content of lipid droplets and fibre-type grouping. Electron 
microscopy showed a large variety of non-specific 
abnormalities including mitochondrial changes, Z-band 
degeneration, myofilament loss and accumulation of intra-
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cellular glycogen. Ten of 12 control subjects showed no 
such changes; minor abnormalities were noted on both light 
and electron microscopy in the rema i ning 2. Muscle 
oxidative capacity (Q02 = 19.5 ± 5. 1 fL 02.min-l ) for 
patients with end-stage renal failure was no t different from 
values for those who had undergone renal transplantation, 
but was lower than values in trained athl etes. 
Thus patients undergoing chronic haemodialysis for chronic 
renal failure have significant morphological abnormalities 
in skeletal muscle. Such changes might explain the impaired 
skeletal muscle function of these patients. 
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CHAPTER 6 
THE EFFECTS OF ATENOLOL OR RECOMBINANT HUMAN ERYTHROPOIETIN 
ON THE EXERCISE TOLERANCE OF PATIENTS WITH END-STAGE RENAL 
FAIWRE RECEIVING CHRONIC HAEMODIALYSIS 
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INTRODUCTION 
Adequate haemodialysis is often insufficient to correct the 
hypertension and anaemia associated with end-stage renal 
failure [Chobanian et al., 1982; Maher, 1989 (a)]. 
Therefore, additional medication may be necessary such as B-
blockers and EPO, respectively. But medications such as B-
blockers reduce the peak exercise heart rates and V02 max of 
healthy subjects [Van Baak, 1988). In contrast, EPO 
increases haemoglobin concentrations and V02 peak in 
patients with end-stage renal failure [Mayer et al., 1988; 
Chapter 5). 
Low peak exercise heart rates and haemoglobin concentrations 
are the two factors most commonly cited in the argument for 
a central (cardiovascular) limitation to exercise in 
patients with end-stage renal failure receiving chronic 
haemodialysis [Chapter 1]. Patients who require either 
medication may therefore demonstrate peak exercise heart 
rates or haemoglobin concentrations significantly different 
from patients not using these drugs. Thus conclusions 
reached regarding factors which limit patients with end-
stage renal failure receiving chronic haemodialysis during 
peak exercise may be erroneous, if patients receiving 
exercise affecting medications are grouped together with 
results from patients who are not using such medications. 
lll 
This study was designed, therefore, to investigate the 
possible effects of non-selective grouping of these patients 
in exercise-related studies. In particular the grouping of 
those patients who are ingesting either Atenolol (lOOmg.day-
1) or receiving EPO therapy, with patients who are on 
neither form of medication. 
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MATERIALS AND METHODS 
Patient selection. Thirty-seven medically stable adult (30 
male and 7 female) patients with chronic end-stage renal 
failure, receiving chronic haemodialysis volunteered for the 
study which had been approved by the Committee for Research 
on Human Subjects of the University of the Witwatersrand. 
Patients were from the Renal Units of the J.G. Strijdom, 
Johannesburg General and Baragwanath Hospitals, and were all 
screened by their respective renal physicians prior to 
entering the study. Informed consent was obtained from each 
patient after detailed description of the protocol. The 
sample of patients was subdivided into three groups 
according to their medication. Group A (n=9) were those 
patients on EPO, Group B (n=7) those on B-blockers (all were 
receiving lOOmg.day-1 dosages of Atenolol) and Group C 
(n=21) those on neither EPO nor B-blockers [Table 6.1]. 
Most patients were receiving phosphate binders (Actal. R) 
and calcium supplements (Titralac. R); neither of which are 
considered to influence exercise performance. Nine patients 
were on either aspirin or persantin. Ten patients were 
receiving the calcium blocker (Nifedipine); two of these 
patients were in Group A, five in Group Band three in Group 
c. 
Exercise tests. Each patient performed a graded exercise 
test to exhaustion for measurement of peak oxygen 
consumption (V02 peakl as well as an isokinetic exercise 
test for measurement of peak torque at three different 
contraction velocities. The patients were required to 
perform exactly the same test protocols as those described 
in Chapter 3. 
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Values for haemoglobin concentration and haematocr i t were 
obtained, prior to any testing, from each patient's files at 
the respective renal haemodialysis units. 
Statistical analysis 
This study is a cross-sectional comparison of 3 groups. 
Data are expressed as mean± SD. 'Any differences between 
the groups were assessed using 1-way ANOVA. If a 
significant difference (p<0.05) between the Groups was 
found, then a Bonferroni procedure was used to determine 
were the difference lay. 
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RESULTS 
Group A (patients on EPO) consisted of 9 (6 male and 3 
female) patients, 25% of the total sample size. Group B 
(patients on B-blockers) consisted of 7 (5 male and 2 
female) patients, 19% of the total sample, whilst Group C 
consisted of 21 (19 male and 2 female) patients, 56% of the 
total sample. 
Anthropomorphic and haematological measurements are reported 
in Table 6.1. There were no significant differences for 
age, height, weight, duration of haemodialysis, haemoglobin 
concentration, or haematocrit between groups. 
Table 6.1. Anthropomorphic and Haematological Measurements 
in the Three Groups of Patients with End-Stage Renal Failure 
A 
n 9 
Age (yrs) 38 ± 9 
Height (cm) 169 ± 9 
Weight (kg) 65 ± 13 
Dialysis 
Duration (mo) 54 ± 52 
Hb (g.dL-1) 
Hct (%) 
8.1 ± 1.7 




38 ± 11 
167 ± 11 
66 ± 11 
23 ± 44 
7.5 ± 0.7 
23 ± 2 
Data are expressed as mean± SD. 
C 
21 
39 ± 10 
169 ± 9 
61 ± 11 
23 ± 32 
8.3 ± 2.6 
25 ± 8 
ABBREVIATIONS: mo=months; Hb=haemoglobin; Hct=haematocrit 
Group A= patients on EPO; Group B = patients on B-blockers; 
Group C = patients requiring neither medication. None of 
the variables in Table 1 was significantly different 
(p>0.05) 
The causes of renal failure are reported in Table 6.2. 
Hypertension was the leading cause of renal failure in all 
the groups. 
Table 6.2. Causes of Renal Failure in Three Groups of 
Patients Receiving Chronic Haemodialysis 





Idiopathic Nephritic Syndrome 
Chronic Pyelonephritis 
Chronic Lupus Nephritis 






























ABBREVIATIONS: Bilat.=Bilateral; FSH=Focal Segmental 
Hyalinosis. Group A= patients on EPO; Group B = patients 




Table 6.3 lists cardiorespiratory variables measured at rest 
and during maximum exercise to exhaustion. Peak oxygen 
consumption was significantly lower (p<0.05) in Group B 
compared to Groups A and C (19.2 ± 2; 15 ± 3.5; and 20.1 ± 5 
ml 02.min-l.kg-l for Groups A; B; and C respectively). 
Resting heart rates were also significantly lower (p<0.05) 
in Group B compared to Groups A and C (88 ± 11; 72 ± 8; 86 
±14 beats.min-1 for Groups A; B; and C respectively) as were 
peak heart rates (158 ± 18; 110 ± 19; 152 ± 16 beats.min-1 
for Groups A; B; and C respectively). 
However, no significant differences were found between peak 
workrate, peak ventilation, blood lactate concentrations at 
rest or at peak exercise, and respiratory exchange ratios. 
The predominant subjective reason for terminating the V02 
peak exercise test was leg fatigue; other reasons included 
chest discomfort, not considered to be angina. 
Table 6.4 lists peak isokinetic muscle strength, expressed 
as peak torque, in ft.lbs, was measured using the Cybex II 
Isokinetic Dynamometer. No significant differences were 
found at any of the limb contraction velocities between any 
measurements in any of the groups. 
Table 6.3. Cardiorespiratory and Metabolic Parameters at 
Rest and during Peak Exercise in Three Groups of Patients 






V02 peak 19.2 ± 2.0 
7 
15.0 ± 3.5 
21 


















98 ± 19 
72.7 ± 30 
88 ± 11 
158 ± 18 
80 ± 19 
56.0 ± 12 
72 ± 8 
110 ± 19 
101 ± 28 
69.7 ± 22 
86 ± 14 





0.84 ± 0.08 0.78 ± 0.05 0.80 ± 0.08 NS 
1.10 ± 0.07 1.10 ± 0.06 1.14 ± 0.08 NS 
9 6 15 
1.86 ± 0.47 1.71 ± 0.63 1.88 ± 0.51 NS 
5.31 ± 2.65 3.09 ± 0.46 4.94 ± 2.22 NS 
Data expressed as mean± SD. 
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ABBREVIATIONS: V02 peak=Peak oxygen consumption; VE 
PEAK=Peak minute ventilation; RQ=Respiratory quotient; 
NS=not significant (p>0.05); *=significant differences were 
between Group A vs Band Group C vs B but not between Group 
A vs c. Group A=patients on EPO; Group B=patients one-
blockers; Group C=patients requiring neither medication 
Table 6.4. Peak Isokinetic Quadriceps Muscle Strength in 
Three Groups of Patients Receiving Chronic Haemodialysis 
Groups 
A B C 
n 9 7 21 
60 89 ± 35 95 ± 21 98 ± 26 
(ft.lbs) 
180 59 ± 27 63 ± 18 65 ± 20 
(ft.lbs) 
240 51 ± 25 55 ± 14 56 ± 18 
(ft.lbs) 
118 
Data expressed as mean± SD. Limb contraction velocities 
measured in degrees.second-1. Peak torque measured in 
foot.pounds (ft.lbs). No significant differences were found 
between any of the groups (p>0.05). 
ABBREVIATIONS: Group A=patients on EPO; Group B=patients on 
B-blockers; Group C=patients requiring neither medication 
Correlation coefficients for V02 peak and variables relating 
to either isokinetic muscle function or blood oxygen 
carrying capacity can be found in Table 6.5. The only 
positive significant correlations (p<0.05) were found in 
Group C relating V02 peak to isokinetic muscle strength. No 
significant correlations (p>0.05) were found between vo2 
peak and haemoglobin concentration. 
TABLE 6.5 CORRELATION COEFFICIENTS FOR PEAK OXYGEN 
CONSUMPTION AND VARIABLES RELATING TO EITHER ISOKINETIC 
MUSCLE FUNCTION OR BLOOD OXYGEN CARRYING CAPACITY 
Group A B C 
n ( 9) (8) (21) 
Values Values Values 
r p r p r p 
Variable 
Isokinetic Muscle Strength 
at 60 deg.sec-1 .43 NS .32 NS .47 <0.05 
at 180 deg.sec-1 .41 NS .22 NS .49 <0.05 
at 240 deg.sec-1 .42 NS .36 NS .49 <0.05 
Blood Oxygen Carrying Capacity 
Hb concentration .02 NS . 53 NS .31 NS 
ABBREVIATIONS: deg.sec-l=degrees per second; NS=not 
significant (p>0.05); Hb=haemoglobin concentration. 
Group A=patients on EPO; Group B=patients on B-blockers; 




This study included any patient who was willing and 
medically able to undergo the testing procedures. The 
finding that 25% and 19% of the total sample size had either 
been treated with EPO or were ingesting B-blocker medication 
respectively and that the leading identifiable cause of 
renal failure was failure secondary to hypertension 
indicates that the effects of these medications on the 
exercise tolerance of patients receiving chronic 
haemodialysis should not be ignored. 
All 3 groups were matched according to age, height, weight, 
duration of haemodialysis, haemoglobin concentration and 
haematocrit. However, patients in Group B were on 100mg 
atenolol.day-1 and patients in Group A were on maintenance 
doses of EPO whereas patients from Group C were receiving 
neither medication. 
The novel finding of this study was that patients receiving 
B-blockers terminated exercise at significantly lower V02 
peak values and heart rates than did patients not receiving 
B-blockers. These findings imply that results from 
exercise-related studies may be altered if these studies 
fail to take account of the grouping of patients who are on 
B-blockers with those who are not. This is especially the 
case if conclusions are to be made with regard to the V02 
peak and to factors limiting exercise tolerance in patients 
with end-stage renal failure. 
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In particular, several studies have reported significant 
improvements in exercise tolerance after a period of 
training. But these studies also report a reduction in the 
number of patients using fl-blockers [Goldberg et al., 1980; 
Hagberg et al., 1983; Goldberg et al., 1983]. The findings 
of this study suggests that a significant percentage of the 
improvements in exercise tolerance may be due to a change in 
medication and may not be entirely due to a training effect. 
Ten percent of patients with end-stage renal failure with 
hypertension cannot be treated by adequate haemodialysis 
alone [Chobanian et al., 1982]. Atenolol, 100mg daily, is 
often the treatment of choice in those patients whose 
hypertension does not respond satisfactorily to 
haemodialysis [Maher, 1989(b)]. B-Blockers produce a 
reduction of heart rate, thereby potentially reducing 
cardiac output, at rest and during exercise [Van Baak, 
1988]. This reduction of cardiac output can lead to 
impaired muscle blood flow [Saltin, 1990] which in turn 
reduces the amount of oxygen reaching the working muscles. 
Thus maximal exercise may be adversely affected by 
medications, such as fl-blockers, which reduce cardiac output 
and skeletal muscle blood flow. 
Peak isokinetic muscle strength, measured during a very 
brief period of exercise, is probably independent of muscle 
blood ·flow and would thus be unaffected by the reduction of 
muscle blood flow described above. Hence, it is not 
surprising that no significant differences in peak muscle 
strength were found between the groups. 
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In Chapter 3, we concluded that isokinetic muscle strength 
predicts V02 peak in patients wi th end-stage renal failure 
who are receiving chronic haemodialysis. However, since 
there were no significant differences in isokinetic muscle 
strength between the three groups yet V02 peak was lower in 
Group B, B-blockers must produce some effect during more 
prolonged exercise which decreases V02 peak· One 
possibility for this is that the V02 peak test measures two 
variables, one of which relates to muscle strength and is 
predicted by the isokinetic muscle strength tests. However 
as the V02 peak lasts for some time, an element of fatigue 
resistance [Coetzer et al., 1993) may be involved. Perhaps 
B-blocking agents increase the rate at which fatigue 
develops during exercise so that persons using these agents 
terminate exercise prematurely, thereby reaching lower V02 
peak values. Furthermore, significant correlations between 
V02 peak and isokinetic muscle strength were found only in 
Group C. This finding, as well as the absence of a 
significant correlation between V02 peak and haemoglobin 
concentration in any of the 3 groups, confirms our previous 
conclusions in Chapter 3. 
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CONCLUSIONS 
A large proportion of patients undergoing chronic 
haemodi alysis require EPO therapy or B-blockers to control 
the i r anaemia and hypertension respectively. Since it has 
been suggested that the exercise tolerance of these patients 
may be limited by a reduced cardiac output, from low heart 
rates, and low arterial content, from anaemia, we decided to 
study the effects of medications which influence both of 
these factors on their V02 peak· 
The results of this study clearly show that patients with 
end-stage renal failure undergoing maintenance haemodialysis 
and receiving B-blockers have significantly lower peak heart 
rates, measured during exhaustive exercise, than patients 
not receiving B-blockers. 
Thus conclusions concerning the role that low peak exercise 
heart rate has in limiting the exercise tolerance of these 
patients must be viewed with caution, if the sample includes 
patients receiving fl-blocker medication. In a recent study, 
Moore et al. 1993, despite acknowledging that propanolol 
biased the heart rate results of 2 of their patients (20% of 
the total sample size) included their results in the final 
analysis. These authors later concluded that exercise 
tolerance was primarily limited by low peak heart rate and 
anaemia. 
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Once their haemoglobin concentrations are corrected, 
patients requiring partial correction of their anaemia 
attain exercise tolerance levels similar to patients not 
requiring correction. Hence inclusion of patients receiving 
EPO in exercise-related studies appear not to adversely 
alter the results. 
However, it appears as if B-blockers can compromise already 
extremely compromised V02 peak levels of patients undergoing 
chronic haemodialysis. 
It is also suggested that any future studies which aim to 
unravel the multitude of possible causes for the low 
exercise tolerance of patients undergoing chronic 




Hypertension and anaemia occur commonly in patients with 
end-stage renal failure undergoing chronic haemodialysis. 
Both hypertension and anaemia are often not controlled by 
adequate haemodialysis or blood transfusions, respectively. 
Atenolol, 100mg daily, is a B-blocker which is often the 
treatment of choice for the hypertension in patients 
receiving chronic haemodialysis. Recombinant human 
erythropoietin (EPO) has proved successful in both partially 
correcting the anaemia associated with end-stage renal 
failure and dramatically improving the exercise tolerance of 
these patients, as shown in Chapter 5. 
Both Atenolol and EPO are capable of influencing V02 peak 
during maximal exercise. This study was designed, 
therefore, to investigate the possible effects of non-
selective grouping of these patients in exercise-related 
studies. In particular patients were grouped into those 
receiving EPO (Group A); or ingesting Atenolol (lOOmg.day-1) 
(Group B) or patients on neither form of medication (Group 
C) • 
Patients were assigned to one of three groups according to 
their medications. Group A (n=9) were patients who were on 
EPO; Group B (n=7) were patients on Atenolol 100mg daily; 
and Group C (n=21) were patients on neither Atenolol nor 
EPO. 
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Peak oxygen consumption [Group A 19.2 ± 2.0; Group B 15 ± 
3.5; and Group C 20.1 ± 5 mL 02.kg-l.min-l] and peak heart 
rates [Group A 158 ± 18; Group B 110 ± 19; and Group C 152 ± 
16] were significantly lower when Group B patients were 
compared with either Group A or Group C. However, no 
significant differences were found for peak isokinetic 
quadriceps muscle strength. Therefore, Atenolol, 100mg 
daily, can significantly lower V02 peak and peak heart rate 
in patients undergoing chronic haemodialysis. 
Thus grouping patients with end-stage renal failure who are 
receiving chronic haemodialysis who receive Atenolol, with 
patients who do not receive Atenolol, in exercise-related 
studies may significantly lower V02 peak and peak heart rate 
of the whole group. This lowering may then lead to 
incorrect conclusions regarding the causes responsible for 
the low exercise tolerance of patients receiving chronic 
haemodialysis. Several studies which suggested that low 
peak heart rate limits exercise tolerance in patients with 
end-stage renal failure have failed to exclude patients 
receiving medication from their sample size. Inclusion of 






The exact sequence of events leading to the pathological 
changes explaining the very low exercise tolerance of patients 
with end-stage renal failure receiving •aintenance 
haemodialysis has yet to be definitively identified. Opinion 
is divided between those who believe that the main cause of 
the poor exercise tolerance in these patients is the reduced 
oxygen carrying capacity of the blood [Barnea et al., 1980; 
Kettner, 1982; Zabetakis et al., 1982; Zanconato et al., 1990; 
Lundin et al., 1991] coupled with low peak exercise heart 
rates causing impaired oxygen delivery to the active muscles 
[Moore et al., 1993{a)], whereas others believe that impaired 
muscle contractile function associated with the renal failure 
is the primary factor [Kettner-Melsheimer et al., 1987; 
Robertson et al., 1990]. Recently it has been suggested that 
in some of these patients, the ability to extract all the 
physiologically available oxygen from the blood may also limit 
exercise tolerance in patients with end-stage renal failure 
undergoing maintenance haemodialysis [Moore et al., 1993{a)]. 
Hence it is argued that either a central limitation of oxygen 
delivery to muscle resulting from the anaemia and an 
associated impairment in oxygen uptake by the active muscles 
[Moore et al., 1993{a)] or impaired skeletal muscular 
contractile function, separate from both the anaemia and the 
postulated impairment in oxygen uptake by the active muscles, 
explains the poor exercise tolerance of these patients. 
On the basis that the mixed venous oxygen content was the 
same, whereas the arterial-venous oxygen difference (A-vo2) 
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and the peak exercise heart rates were less than values 
measured in other trained and sedentary subjects, Moore et al. 
(1993(a)) have argued that anaemia together with impaired 
cardiovascular function and an impaired capacity for skeletal 
muscle to extract oxygen limit the exercise tolerance of 
patients with end-stage renal failure undergoing maintenance 
haemodialysis. 
However they argue that the delivery of oxygen to the active 
•uscles is the aajor factor limiting the exercise tolerance of 
the majority of these patients. 
Furthermore, these authors [Moore et al., 1993(b)] suggest 
that skeletal muscle weakness cannot be responsible for the 
low exercise tolerance in these patients because peak heart 
rates are typically elevated in other groups of patients with 
skeletal muscle disease and are not reduced as is the case in 
patients with end-stage renal failure undergoing maintenance 
haemodialysis. 
However there are two findings in this thesis which are not 
immediately compatible with this finding and hence with the 
hypothesis of Moore et al. (1993(a)). First if oxygen 
delivery is the •ajor factor limiting the exercise tolerance 
of these patients, then the peak blood lactate levels should 
be elevated. Yet they are low (Tables 3.2, 4.3, and 6.3). 
Second, there should be a 'plateau' in oxygen consumption 
during maximal exercise [Noakes, 1988), yet this is also 
clearly not the case (Chapter 3; Figures 3.1 and 4.1). 
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Furthermore, Moore et al. (1993(a)) included patients who were 
on B-blocker therapy in their sample, and despite 
acknowledging the effects of this medication on peak heart 
rates and vo2 peak, they nevertheless concluded that low peak 
exercise heart rates due to the primary disease process, were 
responsible for the poor exercise tolerance of these patients. 
Moore et al. (1993(a)) also suggest that the exercise 
tolerance of certain patients with end-stage renal failure 
undergoing maintenance haemodialysis may be limited by the 
inability to extract all the physiologically available oxygen 
during maximal exercise rather than being limited by oxygen 
delivery. 
This theory may help explain our findings that sub-maximal 
oxygen consumption was identical before and after EPO therapy 
[Chapter 4]. However, as with the theory that a limited 
oxygen delivery limits exercise in these patients, this theory 
can explain neither the low peak blood lactate concentrations 
nor the absence of a 'plateau' in oxygen consumption during 
maximal exercise in these patients. Furthermore, it is 
difficult to conceptualize how patients can switch from one 
category to the other, that is either oxygen flow limited or 
oxygen extraction limited, as a result of either EPO therapy 
or exercise training [Moore et al., 1993(b)]. 
The critical factor that is ignored by those who argue that 
oxygen delivery or utilization is impaired, is that oxygen 
demand is ultimately determined by muscle contractile 
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activity. If muscle contractile activity is limited by muscle 
weakness, in particular a specific myopathy of chronic renal 
failure [Floyd et al., 1974: Chapter 5] or by an impaired 
central motor capacity to recruit skeletal muscle fibres, then 
those diseased muscles will be unable to generate sufficient 
activity to increase oxygen demand sufficiently to tax 
cardiovascular function. Thus all the evidence provided in 
support of an oxygen limitation does not disprove the 
alternate view argued here [Chapter 3] and by other work from 
this laboratory [Kempeneers et al., 1990], that skeletal 
muscle function might limit the exercise tolerance of these 
patients. 
Evidence that peripheral skeletal muscle factors could be an 
important contributor to the poor exercise tolerance of 
patients with end-stage renal failure receiving maintenance 
haemodialysis was provided by several important findings from 
this study. 
Firstly, in patients with end-stage renal failure undergoing 
maintenance haemodialysis, isokinetic muscle strength was a 
better predictor of exercise tolerance than were variables 
determining blood oxygen carrying capacity [Chapter 3]. 
Secondly, the improved exercise tolerance of those patients 
who receive EPO therapy does not appear to be solely due to 
reversal of muscle hypoxia which develops during maximal 
exercise but could result from an effect of EPO therapy on 
skeletal muscle contractile function [Chapter 4]. The finding 
which supports this interpretation is that EPO therapy does 
not increase oxygen consumption during subaaximal exercise 
even at the maximal workrate achieved before EPO therapy 
commenced (Figure 4.1). 
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And thirdly, and perhaps most importantly, we demonstrated 
morphological changes in the muscles of these patients which 
may be sufficiently severe to account for the muscle weakness 
and impaired exercise tolerance found in patients with end-
stage renal failure undergoing maintenance haemodialysis 
[Chapter 5]. 
However as correctly pointed out by Moore et al. (1993(b)), 
patients with end-stage renal failure undergoing maintenance 
haemodialysis terminate exercise with low peak heart rates 
which is not characteristic of patients with skeletal muscle 
disease. 
At present, therefore, neither theory is able to fully explain 
the pathological sequence of events leading to the poor 
exercise tolerance in patients with end-stage renal failure 
undergoing maintenance haemodialysis. It aay, however, be 
possible that impaired central motor drive or a peripheral 
neuropathy, or both, may limit skeletal muscle fibre 
recruitment during prolonged exercise in these patients. 
Reduced muscle fibre recruitment could explain the low peak 
heart rates, ventilation and blood lactate concentrations as 
well the correlation between vo2 peak and isokinetic muscle 
strength. Perhaps in this population, isokinetic muscle 
testing measures only the ability of the patient to recruit 
skeletal muscle. Future investigations should, therefore, 
include EMG activity studies of the lower limb during 
prolonged exercise in patients with end-stage renal failure 
undergoing maintenance haemodialysis. 
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In conclusion, it would appear that the exercise tolerance of 
patients with end-stage renal failure undergoing maintenance 
haemodialysis may be limited by central cardiovascular as well 
as peripheral factors. The aost important of these, so far 
identified, being either a reduced capacity to delivery oxygen 
to the working muscles, resulting from anaemia and low peak 
heart rates, or the ability to extract all the available 
oxygen by the muscles confounded by poor contractile function 
of the skeletal muscles and decreased muscle fibre 
recruitment. 
Low peak exercising heart rates together with low mixed venous 
oxygen contents after maximal exercise provide good evidence 
for a central cardiovascular limitation to exercise in 
patients with end-stage renal failure undergoing maintenance 
haemodialysis. But, in addition, profound skeletal muscle 
weakness which predicts the vo2 peak, low peak blood lactate 
concentrations, the absence of a 'plateau' in oxygen 
consumption during maximal exercise, a reduced ability to 
extract all available oxygen by the muscles toghether with 
severe morphological abnormalities in skeletal auscle, all 
indicate a strong peripheral component to the low exercise 
tolerance of these patients. Thus neither theory appears to 
fit all the findings. It is suggested therefore that, in 
addition to all these abnormalities, skeletal muscle fibre 
recruitment may be deficient in these patients resulting in 
low vo2 peak and peak heart rates, low peak blood lactate 
concentrations, low peak ventilation volumes, and poor 
skeletal muscle function. 
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Invasive techniques to study central cardiovascular function 
plus other investigations perhaps using electromyography and 
magnetic resonance spectroscopy to study skeletal metabolism, 
as well as studies of skeletal muscle contractile function are 
probably required to identify the predominant causes for the 
poor exercise tolerance in patients with end-stage renal 
failure who are undergoing maintenance haemodialysis. 
The aim of this thesis will have been served if it helps to 
direct the attention of renal clinicians and rehabilitation 
specialists to focus on both the peripheral skeletal muscle 
factors as well as the central factors, which compromise the 
exercise tolerance of this particular group of patients. 
For the rehabilitation, both physical and aedical of these 
patients, can only be optimised if all the factors limiting 
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